index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
31101,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Peru,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-38.46,United States,2014,-42.05
31102,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Poland,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,152.5,United States,2014,166.72
31103,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Portugal,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,137.89,United States,2014,150.75
31104,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Qatar,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-30,United States,2014,-32.8
31105,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Romania,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-9.17,United States,2014,-10.02
31106,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Saint Kitts and Nevis,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-66.74,United States,2014,-72.96
31107,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Samoa,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-30.71,United States,2014,-33.58
31108,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Saudi Arabia,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-44.55,United States,2014,-48.7
31109,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Senegal,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-11.86,United States,2014,-12.97
31110,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Singapore,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-10.74,United States,2014,-11.74
31111,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Solomon Islands,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-33.26,United States,2014,-36.36
31112,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Suriname,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-3.83,United States,2014,-4.18
31113,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Tajikistan,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-8.73,United States,2014,-9.54
31114,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,North Macedonia,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-21.82,United States,2014,-23.85
31115,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Timor-Leste,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,1.14,United States,2014,1.25
31116,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Tonga,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-3.18,United States,2014,-3.48
31117,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Tunisia,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-26.38,United States,2014,-28.84
31118,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Turkey,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-15,United States,2014,-16.4
31119,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Turkmenistan,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-16.15,United States,2014,-17.66
31120,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Tuvalu,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-70.74,United States,2014,-77.34
31121,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Ukraine,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,13.88,United States,2014,15.17
31122,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Uzbekistan,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-29.35,United States,2014,-32.08
31123,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Venezuela,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-25,United States,2014,-27.33
31124,Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study,"BACKGROUND: The controlled temperature chain (CTC) strategy allows vaccines to be kept outside the cold chain for a short period of time. In remote rural areas, the CTC strategy for the hepatitis B virus (HBV) birth dose vaccination could improve its geographical coverage and timeliness of delivery, but with additional outreach costs. We assessed the cost-effectiveness of the CTC strategy for the HBV birth dose across six world regions and 72 countries according to their HBV prevalence, delivery costs, and birth dose coverage and timing. METHODS: By use of a mathematical model of perinatal HBV transmission and disease progression, we calculated per 1000 births the total HBV-related disability-adjusted life-years (DALYs) and costs, including vaccine delivery costs and costs associated with HBV-related disease, with and without the CTC strategy. FINDINGS: A CTC strategy produced health benefits in all regions and was cost-saving in the regions of east Asia and Pacific, Latin America and Caribbean, sub-Saharan Africa, and north Africa and Middle East. The CTC strategy cost US$0.15 (IQR -7.11 to 4.75) per DALY averted in the central and eastern Europe and central Asia region and $79.72 (66.47 to 94.47) in the south Asia region. Within individual countries, more savings were achieved and more DALYs averted in areas with above average HBV prevalence, below average birth dose coverage, or later than average birth dose delivery. INTERPRETATION: A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission. FUNDING: Burnet Institute.",2018-99-27176,29773122,Lancet Glob Health,Nick Scott,2018,6 / 6,e659-e667,No,29773122,"Nick Scott; Anna Palmer; Christopher Morgan; Olufunmilayo Lesi; C Wendy Spearman; Mark Sonderup; Margaret Hellard; Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study, Lancet Glob Health, 2018 Jun; 6(6):2214-109X; e659-e667",DALY,Viet Nam,Not Stated,Immunization,Controlled temperature chain for the hepatitis B virus birth dose vaccine vs. Standard/Usual Care- Hepatitis B virus birth dose vaccination delivery/storage without controlled temperature chain strategy,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-12.5,United States,2014,-13.67
31125,"Postintroduction Study of Cost Effectiveness of Pneumococcal Vaccine PCV10 from Public Sector Payer's Perspective in the State of Santa Catarina, Brazil","OBJECTIVES: To evaluate cost effectiveness of 10-valent pneumococcal conjugate vaccine in the routine immunization program for children younger than 5 years in Brazil by a postintroduction study. METHODS: Ecological study of prevaccine (2006-2009) versus postvaccine (2011-2014) period related the changes in mortality rate and hospitalization rate to direct cost of pneumonia treatment from the payer''s perspective to estimate the cost effectiveness regarding lives saved, life-years gained, and disability-adjusted life-year for children younger than 5 years in the southern Brazilian state of Santa Catarina. All-cause pneumonia (ICD-10 J12-J18) deaths, hospital admissions, and associated costs were retrieved from the Brazilian Ministry of Health official Web site. Life expectancy at birth, population, ambulatory costs, cost savings, and plausible range of these parameters were used from published sources. Computer simulations with sensitivity analysis were performed to obtain the cost-effectiveness estimates. RESULTS: About 27 lives were saved and 2573 hospitalizations averted by the 10-valent pneumococcal conjugate vaccine vaccination in the 2011 to 2014 period at the cost of US $24,348 per life-year gained and US $27,748 per disability-adjusted life-year. The latter cost is 81% of Brazilian gross domestic product per capita over the same period. CONCLUSIONS: The vaccine was very cost-effective according to the World Health Organization criterion.",2018-02-27180,29772472,Value Health Reg Issues,Emil Kupek,2018,17 /,109-114,No,29772472,"Emil Kupek; Ilse Viertel; Postintroduction Study of Cost Effectiveness of Pneumococcal Vaccine PCV10 from Public Sector Payer's Perspective in the State of Santa Catarina, Brazil, Value Health Reg Issues, 2018 May 14; 17():2212-1099; 109-114",DALY,Brazil,Not Stated,Immunization,10-valent pneumococcal conjugate vaccine immunization program vs. None,Not Stated,5 Years,Not Stated,"Female, Male",Full,,Not Stated,3.00,27748,United States,2011,31926.38
31126,Choice of time horizon critical in estimating costs and effects of changes to HIV programmes,"BACKGROUND: Uganda changed its antiretroviral therapy guidelines in 2014, increasing the CD4 threshold for antiretroviral therapy initiation from 350 cells/mul to 500 cells/mul. We investigate what effect this change in policy is likely to have on HIV incidence, morbidity, and programme costs, and estimate the cost-effectiveness of the change over different time horizons. METHODS: We used a complex individual-based model of HIV transmission and antiretroviral therapy scale-up in Uganda. 100 model fits were generated by fitting the model to 51 demographic, sexual behaviour, and epidemiological calibration targets, varying 96 input parameters, using history matching with model emulation. An additional 19 cost and disability weight parameters were varied during the analysis of the model results. For each model fit, the model was run to 2030, with and without the change in threshold to 500 cells/mul. RESULTS: The change in threshold led to a 9.7% (90% plausible range: 4.3%-15.0%) reduction in incidence in 2030, and averted 278,944 (118,452-502,790) DALYs, at a total cost of $28M (-$142M to +$195M). The cost per disability adjusted life year (DALY) averted fell over time, from $3238 (-$125 to +$29,969) in 2014 to $100 (-$499 to +$785) in 2030. The change in threshold was cost-effective (cost <3xUganda''s per capita GDP per DALY averted) by 2018, and highly cost-effective (cost <Uganda''s per capita GDP per DALY averted) by 2022, for more than 50% of parameter sets. CONCLUSIONS: Model results suggest that the change in threshold is unlikely to have been cost-effective to date, but is likely to be highly cost-effective in Uganda by 2030. The time horizon needs to be chosen carefully when projecting intervention effects. Large amounts of uncertainty in our results demonstrates the need to comprehensively incorporate uncertainties in model parameterisation.",2018-99-27189,29768457,PLoS One,Nicky McCreesh,2018,13 / 5,e0196480,No,29768457,"Nicky McCreesh; Ioannis Andrianakis; Rebecca N Nsubuga; Mark Strong; Ian Vernon; Trevelyan J McKinley; Jeremy E Oakley; Michael Goldstein; Richard Hayes; Richard G White; Choice of time horizon critical in estimating costs and effects of changes to HIV programmes, PLoS One , 2018; 13(5):1932-6203; e0196480",DALY,Uganda,Not Stated,"Maternal / Neonatal / Reproductive Care, Pharmaceutical, Other",Not Stated,Not Stated,64 Years,12 Years,"Female, Male",Full,"Many, in sensitivity analysis",3.00,3.00,3238,United States,2015,3535.74
31127,Choice of time horizon critical in estimating costs and effects of changes to HIV programmes,"BACKGROUND: Uganda changed its antiretroviral therapy guidelines in 2014, increasing the CD4 threshold for antiretroviral therapy initiation from 350 cells/mul to 500 cells/mul. We investigate what effect this change in policy is likely to have on HIV incidence, morbidity, and programme costs, and estimate the cost-effectiveness of the change over different time horizons. METHODS: We used a complex individual-based model of HIV transmission and antiretroviral therapy scale-up in Uganda. 100 model fits were generated by fitting the model to 51 demographic, sexual behaviour, and epidemiological calibration targets, varying 96 input parameters, using history matching with model emulation. An additional 19 cost and disability weight parameters were varied during the analysis of the model results. For each model fit, the model was run to 2030, with and without the change in threshold to 500 cells/mul. RESULTS: The change in threshold led to a 9.7% (90% plausible range: 4.3%-15.0%) reduction in incidence in 2030, and averted 278,944 (118,452-502,790) DALYs, at a total cost of $28M (-$142M to +$195M). The cost per disability adjusted life year (DALY) averted fell over time, from $3238 (-$125 to +$29,969) in 2014 to $100 (-$499 to +$785) in 2030. The change in threshold was cost-effective (cost <3xUganda''s per capita GDP per DALY averted) by 2018, and highly cost-effective (cost <Uganda''s per capita GDP per DALY averted) by 2022, for more than 50% of parameter sets. CONCLUSIONS: Model results suggest that the change in threshold is unlikely to have been cost-effective to date, but is likely to be highly cost-effective in Uganda by 2030. The time horizon needs to be chosen carefully when projecting intervention effects. Large amounts of uncertainty in our results demonstrates the need to comprehensively incorporate uncertainties in model parameterisation.",2018-99-27189,29768457,PLoS One,Nicky McCreesh,2018,13 / 5,e0196480,No,29768457,"Nicky McCreesh; Ioannis Andrianakis; Rebecca N Nsubuga; Mark Strong; Ian Vernon; Trevelyan J McKinley; Jeremy E Oakley; Michael Goldstein; Richard Hayes; Richard G White; Choice of time horizon critical in estimating costs and effects of changes to HIV programmes, PLoS One , 2018; 13(5):1932-6203; e0196480",DALY,Uganda,Not Stated,"Maternal / Neonatal / Reproductive Care, Pharmaceutical, Other",HIV-positive individuals with CD4 count < 500 cells/microliter receive antiretroviral therapy vs. HIV-positive individuals with CD4 count < 350 cells/microliter receive antiretroviral therapy,Not Stated,64 Years,12 Years,"Female, Male",Full,"Many, in sensitivity analysis",3.00,3.00,100,United States,2015,109.2
31128,Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran,"OBJECTIVES: To estimate the cost effectiveness of introducing the quadrivalent human papillomavirus (HPV) vaccine into the national immunization program of Iran. METHODS: The CERVIVAC cost-effectiveness model was used to calculate incremental cost per averted disability-adjusted life-year by vaccination compared with no vaccination from both governmental and societal perspectives. Calculations were based on epidemiologic parameters from the Iran National Cancer Registry and other national data sources as well as from literature review. We estimated all direct and indirect costs of cervical cancer treatment and vaccination program. All future costs and benefits were discounted at 3% per year and deterministic sensitivity analysis was used. RESULTS: During a 10-year period, HPV vaccination was estimated to avert 182 cervical cancer cases and 20 deaths at a total vaccination cost of US $23,459,897; total health service cost prevented because of HPV vaccination was estimated to be US $378,646 and US $691,741 from the governmental and societal perspective, respectively. Incremental cost per disability-adjusted life-year averted within 10 years was estimated to be US $15,205 and US $14,999 from the governmental and societal perspective, respectively, and both are higher than 3 times the gross domestic product per capita of Iran (US $14,289). Sensitivity analysis showed variation in vaccine price, and the number of doses has the greatest volatility on the incremental cost-effectiveness ratio. Using a two-dose vaccination program could be cost-effective from the societal perspective (incremental cost-effectiveness ratio = US $11,849). CONCLUSIONS: Introducing a three-dose HPV vaccination program is currently not cost-effective in Iran. Because vaccine supplies cost is the most important parameter in this evaluation, considering a two-dose schedule or reducing vaccine prices has an impact on final conclusions.",2018-99-27366,29698864,Value Health Reg Issues,Mohsen Yaghoubi,2018,15 /,112-119,No,29698864,"Mohsen Yaghoubi; Marzieh Nojomi; Atefeh Vaezi; Vida Erfani; Susan Mahmoudi; Khadijeh Ezoji; Seyed Mohsen Zahraei; Irtaza Chaudhri; Maziar Moradi-Lakeh; Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran, Value Health Reg Issues, 2018 May; 15():2212-1099; 112-119",DALY,Iran,Not Stated,Immunization,Human papillomavirus national immunization program vs. None,Not Stated,9 Years,9 Years,Female,Full,,3.00,3.00,14999,United States,2015,16378.18
31129,"Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making","BACKGROUND: Senegal''s National Malaria Control Programme (NMCP) implements control interventions in the form of targeted packages: (1) scale-up for impact (SUFI), which includes bed nets, intermittent preventive treatment in pregnancy, rapid diagnostic tests, and artemisinin combination therapy; (2) SUFI + reactive case investigation (focal test and treat); (3) SUFI + indoor residual spraying (IRS); (4) SUFI + seasonal malaria chemoprophylaxis (SMC); and, (5) SUFI + SMC + IRS. This study estimates the cost effectiveness of each of these packages to provide the NMCP with data for improving allocative efficiency and programmatic decision-making. METHODS: This study is a retrospective analysis for the period 2013-2014 covering all 76 Senegal districts. The yearly implementation cost for each intervention was estimated and the information was aggregated into a package cost for all covered districts. The change in the burden of malaria associated with each package was estimated using the number of disability adjusted life-years (DALYs) averted. The cost effectiveness (cost per DALY averted) was then calculated for each package. RESULTS: The cost per DALY averted ranged from $76 to $1591 across packages. Using World Health Organization standards, 4 of the 5 packages were ""very cost effective"" (less than Senegal''s GDP per capita). Relative to the 2 other packages implemented in malaria control districts, the SUFI + SMC package was the most cost-effective package at $76 per DALY averted. SMC seems to make IRS more cost effective: $582 per DALY averted for SUFI + IRS compared with $272 for the SUFI + IRS + SMC package. The SUFI + focal test and treat, implemented in malaria elimination districts, had a cost per DALY averted of $1591 and was only ""cost-effective"" (less than three times Senegal''s per capita GDP). CONCLUSION: Senegal''s choice of deploying malaria interventions by packages seems to be effectively targeting high burden areas with a wide range of interventions. However, not all districts showed the same level of performance, indicating that efficiency gains are still possible.",2018-99-27512,29636051,Malar J,Sophie Faye,2018,17 / 1,159,No,29636051,"Sophie Faye; Altea Cico; Alioune Badara Gueye; Elaine Baruwa; Benjamin Johns; Medoune Ndiop; Martin Alilio; Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making, Malar J, 2018 Apr 10; 17(1):1475-2875; 159",DALY,Senegal,Not Stated,"Diagnostic, Environmental, Pharmaceutical",Scale-up for impact malaria intervention package vs. None,Not Stated,Not Stated,19 Years,Not Stated,Full,,Not Stated,Not Stated,130,United States,2014,142.12
31130,"Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making","BACKGROUND: Senegal''s National Malaria Control Programme (NMCP) implements control interventions in the form of targeted packages: (1) scale-up for impact (SUFI), which includes bed nets, intermittent preventive treatment in pregnancy, rapid diagnostic tests, and artemisinin combination therapy; (2) SUFI + reactive case investigation (focal test and treat); (3) SUFI + indoor residual spraying (IRS); (4) SUFI + seasonal malaria chemoprophylaxis (SMC); and, (5) SUFI + SMC + IRS. This study estimates the cost effectiveness of each of these packages to provide the NMCP with data for improving allocative efficiency and programmatic decision-making. METHODS: This study is a retrospective analysis for the period 2013-2014 covering all 76 Senegal districts. The yearly implementation cost for each intervention was estimated and the information was aggregated into a package cost for all covered districts. The change in the burden of malaria associated with each package was estimated using the number of disability adjusted life-years (DALYs) averted. The cost effectiveness (cost per DALY averted) was then calculated for each package. RESULTS: The cost per DALY averted ranged from $76 to $1591 across packages. Using World Health Organization standards, 4 of the 5 packages were ""very cost effective"" (less than Senegal''s GDP per capita). Relative to the 2 other packages implemented in malaria control districts, the SUFI + SMC package was the most cost-effective package at $76 per DALY averted. SMC seems to make IRS more cost effective: $582 per DALY averted for SUFI + IRS compared with $272 for the SUFI + IRS + SMC package. The SUFI + focal test and treat, implemented in malaria elimination districts, had a cost per DALY averted of $1591 and was only ""cost-effective"" (less than three times Senegal''s per capita GDP). CONCLUSION: Senegal''s choice of deploying malaria interventions by packages seems to be effectively targeting high burden areas with a wide range of interventions. However, not all districts showed the same level of performance, indicating that efficiency gains are still possible.",2018-99-27512,29636051,Malar J,Sophie Faye,2018,17 / 1,159,No,29636051,"Sophie Faye; Altea Cico; Alioune Badara Gueye; Elaine Baruwa; Benjamin Johns; Medoune Ndiop; Martin Alilio; Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making, Malar J, 2018 Apr 10; 17(1):1475-2875; 159",DALY,Senegal,Not Stated,"Diagnostic, Environmental, Pharmaceutical",Scale-up for impact malaria intervention package plus indoor residual spraying vs. None,Not Stated,Not Stated,19 Years,Not Stated,Full,,Not Stated,Not Stated,582,United States,2014,636.27
31131,"Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making","BACKGROUND: Senegal''s National Malaria Control Programme (NMCP) implements control interventions in the form of targeted packages: (1) scale-up for impact (SUFI), which includes bed nets, intermittent preventive treatment in pregnancy, rapid diagnostic tests, and artemisinin combination therapy; (2) SUFI + reactive case investigation (focal test and treat); (3) SUFI + indoor residual spraying (IRS); (4) SUFI + seasonal malaria chemoprophylaxis (SMC); and, (5) SUFI + SMC + IRS. This study estimates the cost effectiveness of each of these packages to provide the NMCP with data for improving allocative efficiency and programmatic decision-making. METHODS: This study is a retrospective analysis for the period 2013-2014 covering all 76 Senegal districts. The yearly implementation cost for each intervention was estimated and the information was aggregated into a package cost for all covered districts. The change in the burden of malaria associated with each package was estimated using the number of disability adjusted life-years (DALYs) averted. The cost effectiveness (cost per DALY averted) was then calculated for each package. RESULTS: The cost per DALY averted ranged from $76 to $1591 across packages. Using World Health Organization standards, 4 of the 5 packages were ""very cost effective"" (less than Senegal''s GDP per capita). Relative to the 2 other packages implemented in malaria control districts, the SUFI + SMC package was the most cost-effective package at $76 per DALY averted. SMC seems to make IRS more cost effective: $582 per DALY averted for SUFI + IRS compared with $272 for the SUFI + IRS + SMC package. The SUFI + focal test and treat, implemented in malaria elimination districts, had a cost per DALY averted of $1591 and was only ""cost-effective"" (less than three times Senegal''s per capita GDP). CONCLUSION: Senegal''s choice of deploying malaria interventions by packages seems to be effectively targeting high burden areas with a wide range of interventions. However, not all districts showed the same level of performance, indicating that efficiency gains are still possible.",2018-99-27512,29636051,Malar J,Sophie Faye,2018,17 / 1,159,No,29636051,"Sophie Faye; Altea Cico; Alioune Badara Gueye; Elaine Baruwa; Benjamin Johns; Medoune Ndiop; Martin Alilio; Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making, Malar J, 2018 Apr 10; 17(1):1475-2875; 159",DALY,Senegal,Not Stated,"Diagnostic, Environmental, Pharmaceutical",Scale-up for impact malaria intervention package plus seasonal malaria chemoprophylaxis vs. None,Not Stated,Not Stated,19 Years,Not Stated,Full,,Not Stated,Not Stated,76,United States,2014,83.09
31132,"Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making","BACKGROUND: Senegal''s National Malaria Control Programme (NMCP) implements control interventions in the form of targeted packages: (1) scale-up for impact (SUFI), which includes bed nets, intermittent preventive treatment in pregnancy, rapid diagnostic tests, and artemisinin combination therapy; (2) SUFI + reactive case investigation (focal test and treat); (3) SUFI + indoor residual spraying (IRS); (4) SUFI + seasonal malaria chemoprophylaxis (SMC); and, (5) SUFI + SMC + IRS. This study estimates the cost effectiveness of each of these packages to provide the NMCP with data for improving allocative efficiency and programmatic decision-making. METHODS: This study is a retrospective analysis for the period 2013-2014 covering all 76 Senegal districts. The yearly implementation cost for each intervention was estimated and the information was aggregated into a package cost for all covered districts. The change in the burden of malaria associated with each package was estimated using the number of disability adjusted life-years (DALYs) averted. The cost effectiveness (cost per DALY averted) was then calculated for each package. RESULTS: The cost per DALY averted ranged from $76 to $1591 across packages. Using World Health Organization standards, 4 of the 5 packages were ""very cost effective"" (less than Senegal''s GDP per capita). Relative to the 2 other packages implemented in malaria control districts, the SUFI + SMC package was the most cost-effective package at $76 per DALY averted. SMC seems to make IRS more cost effective: $582 per DALY averted for SUFI + IRS compared with $272 for the SUFI + IRS + SMC package. The SUFI + focal test and treat, implemented in malaria elimination districts, had a cost per DALY averted of $1591 and was only ""cost-effective"" (less than three times Senegal''s per capita GDP). CONCLUSION: Senegal''s choice of deploying malaria interventions by packages seems to be effectively targeting high burden areas with a wide range of interventions. However, not all districts showed the same level of performance, indicating that efficiency gains are still possible.",2018-99-27512,29636051,Malar J,Sophie Faye,2018,17 / 1,159,No,29636051,"Sophie Faye; Altea Cico; Alioune Badara Gueye; Elaine Baruwa; Benjamin Johns; Medoune Ndiop; Martin Alilio; Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making, Malar J, 2018 Apr 10; 17(1):1475-2875; 159",DALY,Senegal,Not Stated,"Diagnostic, Environmental, Pharmaceutical",Scale-up for impact malaria intervention package plus indoor residual spraying plus seasonal malaria chemoprophylaxis vs. None,Not Stated,Not Stated,19 Years,Not Stated,Full,,Not Stated,Not Stated,272,United States,2014,297.36
31133,"Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making","BACKGROUND: Senegal''s National Malaria Control Programme (NMCP) implements control interventions in the form of targeted packages: (1) scale-up for impact (SUFI), which includes bed nets, intermittent preventive treatment in pregnancy, rapid diagnostic tests, and artemisinin combination therapy; (2) SUFI + reactive case investigation (focal test and treat); (3) SUFI + indoor residual spraying (IRS); (4) SUFI + seasonal malaria chemoprophylaxis (SMC); and, (5) SUFI + SMC + IRS. This study estimates the cost effectiveness of each of these packages to provide the NMCP with data for improving allocative efficiency and programmatic decision-making. METHODS: This study is a retrospective analysis for the period 2013-2014 covering all 76 Senegal districts. The yearly implementation cost for each intervention was estimated and the information was aggregated into a package cost for all covered districts. The change in the burden of malaria associated with each package was estimated using the number of disability adjusted life-years (DALYs) averted. The cost effectiveness (cost per DALY averted) was then calculated for each package. RESULTS: The cost per DALY averted ranged from $76 to $1591 across packages. Using World Health Organization standards, 4 of the 5 packages were ""very cost effective"" (less than Senegal''s GDP per capita). Relative to the 2 other packages implemented in malaria control districts, the SUFI + SMC package was the most cost-effective package at $76 per DALY averted. SMC seems to make IRS more cost effective: $582 per DALY averted for SUFI + IRS compared with $272 for the SUFI + IRS + SMC package. The SUFI + focal test and treat, implemented in malaria elimination districts, had a cost per DALY averted of $1591 and was only ""cost-effective"" (less than three times Senegal''s per capita GDP). CONCLUSION: Senegal''s choice of deploying malaria interventions by packages seems to be effectively targeting high burden areas with a wide range of interventions. However, not all districts showed the same level of performance, indicating that efficiency gains are still possible.",2018-99-27512,29636051,Malar J,Sophie Faye,2018,17 / 1,159,No,29636051,"Sophie Faye; Altea Cico; Alioune Badara Gueye; Elaine Baruwa; Benjamin Johns; Medoune Ndiop; Martin Alilio; Scaling up malaria intervention ""packages"" in Senegal: using cost effectiveness data for improving allocative efficiency and programmatic decision-making, Malar J, 2018 Apr 10; 17(1):1475-2875; 159",DALY,Senegal,Not Stated,"Diagnostic, Environmental, Pharmaceutical",Scale-up for impact malaria intervention package reactive case investigation (focal test and treat) vs. None,Not Stated,Not Stated,19 Years,Not Stated,Full,,Not Stated,Not Stated,1591,United States,2014,1739.36
31134,"Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia","BACKGROUND: The Colombian health authorities introduced the pneumococcal conjugated vaccine and the seasonal influenza vaccine into the national immunization schedule for children in 2009 and 2007, respectively. Despite this, the health authorities continue to be concerned about the high economic and disease burden among children from low-income households caused by these vaccine-preventable diseases. OBJECTIVES: 1) To evaluate the potential health outcomes of four vaccination strategies for subsidized children younger than 5 years in a low-income district in Colombia from a public, direct medical health care perspective. 2) To perform univariate, multivariate, and probabilistic sensitivity analysis to evaluate the robustness of these results. METHODS: We built a Markov deterministic cohort model to evaluate five consecutive cohorts across four alternative situations: 1) no vaccination; 2) vaccination with the 10-valent pneumococcal conjugate vaccine (PCV10 vaccine); 3) vaccination with the trivalent inactivated vaccine (TIV) annually; and 4) combined vaccination with PCV10 vaccine and TIV. RESULTS: The introduction of PCV10 vaccine and TIV and their combined use in particular would be highly cost-effective in comparison to no vaccination. For the combined vaccination with PCV10 vaccine and TIV, the incremental cost-effectiveness ratio would be $1,280 per disability-adjusted life-year (DALY) averted, the total incremental cost of the vaccination program would be $776,800, and it would avert four deaths and 332 DALYs for the five cohorts. CONCLUSIONS: The introduction of PCV10 vaccine and TIV would be highly cost-effective from a public, direct medical health care perspective. Despite these results, we have not observed decreases in severity or hospitalizations. Our findings highlight the need for further studies of the immunization campaign indicators and socioeconomic indicators for this low-income community.",2018-99-27539,29626706,Value Health Reg Issues,Carlos Lara,2018,17 /,21-31,No,29626706,"Carlos Lara; Diana De Graeve; Fabian Franco; Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia, Value Health Reg Issues, 2018 May 14; 17():2212-1099; 21-31",DALY,Colombia,Not Stated,Immunization,10-valent pneumococcal conjugate vaccine vs. None,"San Cristobal district of Bogota, Colombia",5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,1417,International,2008,1703.34
31135,"Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia","BACKGROUND: The Colombian health authorities introduced the pneumococcal conjugated vaccine and the seasonal influenza vaccine into the national immunization schedule for children in 2009 and 2007, respectively. Despite this, the health authorities continue to be concerned about the high economic and disease burden among children from low-income households caused by these vaccine-preventable diseases. OBJECTIVES: 1) To evaluate the potential health outcomes of four vaccination strategies for subsidized children younger than 5 years in a low-income district in Colombia from a public, direct medical health care perspective. 2) To perform univariate, multivariate, and probabilistic sensitivity analysis to evaluate the robustness of these results. METHODS: We built a Markov deterministic cohort model to evaluate five consecutive cohorts across four alternative situations: 1) no vaccination; 2) vaccination with the 10-valent pneumococcal conjugate vaccine (PCV10 vaccine); 3) vaccination with the trivalent inactivated vaccine (TIV) annually; and 4) combined vaccination with PCV10 vaccine and TIV. RESULTS: The introduction of PCV10 vaccine and TIV and their combined use in particular would be highly cost-effective in comparison to no vaccination. For the combined vaccination with PCV10 vaccine and TIV, the incremental cost-effectiveness ratio would be $1,280 per disability-adjusted life-year (DALY) averted, the total incremental cost of the vaccination program would be $776,800, and it would avert four deaths and 332 DALYs for the five cohorts. CONCLUSIONS: The introduction of PCV10 vaccine and TIV would be highly cost-effective from a public, direct medical health care perspective. Despite these results, we have not observed decreases in severity or hospitalizations. Our findings highlight the need for further studies of the immunization campaign indicators and socioeconomic indicators for this low-income community.",2018-99-27539,29626706,Value Health Reg Issues,Carlos Lara,2018,17 /,21-31,No,29626706,"Carlos Lara; Diana De Graeve; Fabian Franco; Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia, Value Health Reg Issues, 2018 May 14; 17():2212-1099; 21-31",DALY,Colombia,Not Stated,Immunization,Trivalent inactivated vaccine vs. None,"San Cristobal district of Bogota, Colombia",5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,-1358.92,International,2008,-1633.53
31136,"Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia","BACKGROUND: The Colombian health authorities introduced the pneumococcal conjugated vaccine and the seasonal influenza vaccine into the national immunization schedule for children in 2009 and 2007, respectively. Despite this, the health authorities continue to be concerned about the high economic and disease burden among children from low-income households caused by these vaccine-preventable diseases. OBJECTIVES: 1) To evaluate the potential health outcomes of four vaccination strategies for subsidized children younger than 5 years in a low-income district in Colombia from a public, direct medical health care perspective. 2) To perform univariate, multivariate, and probabilistic sensitivity analysis to evaluate the robustness of these results. METHODS: We built a Markov deterministic cohort model to evaluate five consecutive cohorts across four alternative situations: 1) no vaccination; 2) vaccination with the 10-valent pneumococcal conjugate vaccine (PCV10 vaccine); 3) vaccination with the trivalent inactivated vaccine (TIV) annually; and 4) combined vaccination with PCV10 vaccine and TIV. RESULTS: The introduction of PCV10 vaccine and TIV and their combined use in particular would be highly cost-effective in comparison to no vaccination. For the combined vaccination with PCV10 vaccine and TIV, the incremental cost-effectiveness ratio would be $1,280 per disability-adjusted life-year (DALY) averted, the total incremental cost of the vaccination program would be $776,800, and it would avert four deaths and 332 DALYs for the five cohorts. CONCLUSIONS: The introduction of PCV10 vaccine and TIV would be highly cost-effective from a public, direct medical health care perspective. Despite these results, we have not observed decreases in severity or hospitalizations. Our findings highlight the need for further studies of the immunization campaign indicators and socioeconomic indicators for this low-income community.",2018-99-27539,29626706,Value Health Reg Issues,Carlos Lara,2018,17 /,21-31,No,29626706,"Carlos Lara; Diana De Graeve; Fabian Franco; Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia, Value Health Reg Issues, 2018 May 14; 17():2212-1099; 21-31",DALY,Colombia,Not Stated,Immunization,10-valent pneumococcal conjugate vaccine and trivalent inactivated vaccine vs. None,"San Cristobal district of Bogota, Colombia",5 Years,Not Stated,"Female, Male",Full,,3.00,3.00,1280,International,2008,1538.66
31137,Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings,"Background: A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB). The contexts in which 3HP may be cost-effective compared to IPT among people living with human immunodeficiency virus are unknown. Methods: We used a Markov state transition model to estimate the incremental cost-effectiveness of 3HP relative to IPT in high-burden settings, using a cohort of 1000 patients in a Ugandan HIV clinic as an emblematic scenario. Cost-effectiveness was expressed as 2017 US dollars per disability-adjusted life year (DALY) averted from a healthcare perspective over a 20-year time horizon. We explored the conditions under which 3HP would be considered cost-effective relative to IPT. Results: Per 1000 individuals on antiretroviral therapy in the reference scenario, treatment with 3HP rather than IPT was estimated to avert 9 cases of TB and 1 death, costing $9402 per DALY averted relative to IPT. Cost-effectiveness depended strongly on the price of rifapentine, completion of 3HP, and prevalence of latent TB. At a willingness to pay of $1000 per DALY averted, 3HP is likely to be cost-effective relative to IPT only if the price of rifapentine can be greatly reduced (to approximately $20 per course) and high treatment completion (85%) can be achieved. Conclusions: 3HP may be a cost-effective alternative to IPT in high-burden settings, but cost-effectiveness depends on the price of rifapentine, achievable completion rates, and local willingness to pay.",2018-99-27561,29617965,Clin Infect Dis,Karl T Johnson,2018,67 / 7,1072-1078,No,29617965,"Karl T Johnson; Gavin J Churchyard; Hojoon Sohn; David W Dowdy; Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings, Clin Infect Dis, 2018 Sep 14; 67(7):1537-6591; 1072-1078",DALY,Uganda,Not Stated,Pharmaceutical,Regimen of 9 months of daily isoniazid (isoniazid preventive therapy) vs. None,Taking antiretroviral therapy,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,225.03,United States,2017,237.6
31138,Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings,"Background: A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB). The contexts in which 3HP may be cost-effective compared to IPT among people living with human immunodeficiency virus are unknown. Methods: We used a Markov state transition model to estimate the incremental cost-effectiveness of 3HP relative to IPT in high-burden settings, using a cohort of 1000 patients in a Ugandan HIV clinic as an emblematic scenario. Cost-effectiveness was expressed as 2017 US dollars per disability-adjusted life year (DALY) averted from a healthcare perspective over a 20-year time horizon. We explored the conditions under which 3HP would be considered cost-effective relative to IPT. Results: Per 1000 individuals on antiretroviral therapy in the reference scenario, treatment with 3HP rather than IPT was estimated to avert 9 cases of TB and 1 death, costing $9402 per DALY averted relative to IPT. Cost-effectiveness depended strongly on the price of rifapentine, completion of 3HP, and prevalence of latent TB. At a willingness to pay of $1000 per DALY averted, 3HP is likely to be cost-effective relative to IPT only if the price of rifapentine can be greatly reduced (to approximately $20 per course) and high treatment completion (85%) can be achieved. Conclusions: 3HP may be a cost-effective alternative to IPT in high-burden settings, but cost-effectiveness depends on the price of rifapentine, achievable completion rates, and local willingness to pay.",2018-99-27561,29617965,Clin Infect Dis,Karl T Johnson,2018,67 / 7,1072-1078,No,29617965,"Karl T Johnson; Gavin J Churchyard; Hojoon Sohn; David W Dowdy; Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings, Clin Infect Dis, 2018 Sep 14; 67(7):1537-6591; 1072-1078",DALY,Uganda,Not Stated,Pharmaceutical,Regimen of 3 months (12 doses) of weekly isoniazid and rifapentine vs. None,Taking antiretroviral therapy,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,230.69,United States,2017,243.58
31139,Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings,"Background: A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB). The contexts in which 3HP may be cost-effective compared to IPT among people living with human immunodeficiency virus are unknown. Methods: We used a Markov state transition model to estimate the incremental cost-effectiveness of 3HP relative to IPT in high-burden settings, using a cohort of 1000 patients in a Ugandan HIV clinic as an emblematic scenario. Cost-effectiveness was expressed as 2017 US dollars per disability-adjusted life year (DALY) averted from a healthcare perspective over a 20-year time horizon. We explored the conditions under which 3HP would be considered cost-effective relative to IPT. Results: Per 1000 individuals on antiretroviral therapy in the reference scenario, treatment with 3HP rather than IPT was estimated to avert 9 cases of TB and 1 death, costing $9402 per DALY averted relative to IPT. Cost-effectiveness depended strongly on the price of rifapentine, completion of 3HP, and prevalence of latent TB. At a willingness to pay of $1000 per DALY averted, 3HP is likely to be cost-effective relative to IPT only if the price of rifapentine can be greatly reduced (to approximately $20 per course) and high treatment completion (85%) can be achieved. Conclusions: 3HP may be a cost-effective alternative to IPT in high-burden settings, but cost-effectiveness depends on the price of rifapentine, achievable completion rates, and local willingness to pay.",2018-99-27561,29617965,Clin Infect Dis,Karl T Johnson,2018,67 / 7,1072-1078,No,29617965,"Karl T Johnson; Gavin J Churchyard; Hojoon Sohn; David W Dowdy; Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings, Clin Infect Dis, 2018 Sep 14; 67(7):1537-6591; 1072-1078",DALY,Uganda,Not Stated,Pharmaceutical,Regimen of 3 months (12 doses) of weekly isoniazid and rifapentine vs. Regimen of isoniazid preventive therapy (9 months of daily isoniazid) (IPT),Taking antiretroviral therapy,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,9402,United States,2017,9927.14
31140,Cost and Cost-Effectiveness of a Demand Creation Intervention to Increase Uptake of Voluntary Medical Male Circumcision in Tanzania: Spending More to Spend Less,"BACKGROUND: Although voluntary medical male circumcision (VMMC) reduces the risk of HIV acquisition, demand for services is lower among men in most at-risk age groups (ages 20-34 years). A randomized controlled trial was conducted to assess the effectiveness of locally-tailored demand creation activities (including mass media, community mobilization, and targeted service delivery) in increasing uptake of campaign-delivered VMMC among men aged 20-34 years. We conducted an economic evaluation to understand the intervention''s cost and cost-effectiveness. SETTING: Tanzania (Njombe and Tabora regions). METHODS: Cost data were collected on surgery, demand creation activities, and monitoring and supervision related to VMMC implementation across clusters in both trial arms, as well as start-up activities for the intervention arms. The Decision Makers'' Program Planning Tool was used to estimate the number of HIV infections averted and related cost savings, given the total VMMCs per cluster. Disability-adjusted life years were calculated and used to estimate incremental cost-effectiveness ratios. RESULTS: Client load was higher in the intervention arms than in the control arms: 4394 vs. 2901 in Tabora and 1797 vs. 1025 in Njombe, respectively. Despite additional costs of tailored demand creation, demand increased more than proportionally: mean costs per VMMC in the intervention arms were $62 in Tabora and $130 in Njombe, and in the control arms $70 and $191, respectively. More infections were averted in the intervention arm than in the control arm in Tabora (123 vs. 67, respectively) and in Njombe (164 vs. 102, respectively). The intervention dominated the control because it was both less costly and more effective. Cost savings were observed in both regions stemming from the antiretroviral treatment costs averted as a result of the VMMCs performed. CONCLUSIONS: Spending more to address local preferences as a way to increase uptake of VMMC can be cost-saving.",2018-01-27681,29557854,J Acquir Immune Defic Syndr,Sergio Torres-Rueda,2018,78 / 3,291-299,No,29557854,"Sergio Torres-Rueda; Mwita Wambura; Helen A Weiss; Marya Plotkin; Katharine Kripke; Joseph Chilongani; Hally Mahler; Evodius Kuringe; Maende Makokha; Augustino Hellar; Carl Schutte; Kokuhumbya J Kazaura; Daimon Simbeye; Gerry Mshana; Natasha Larke; Gissenge Lija; John Changalucha; Anna Vassall; Richard Hayes; Jonathan M Grund; Fern Terris-Prestholt; Cost and Cost-Effectiveness of a Demand Creation Intervention to Increase Uptake of Voluntary Medical Male Circumcision in Tanzania: Spending More to Spend Less, J Acquir Immune Defic Syndr, 2018 Jul 1; 78(3):1525-4135; 291-299",DALY,Tanzania,Not Stated,"Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Surgical","Locally-tailored demand creation and delivery of Voluntary Medical Male Circumcision services to prevent HIV transmission vs. Standard demand creation and delivery of Voluntary Medical Male Circumcision (VMMC) services: mass media engagement, community mobilization, targeted service delivery",Tabora region,40 Years,19 Years,Male,Full,,3.00,3.00,143,United States,2015,156.15
31141,Cost and Cost-Effectiveness of a Demand Creation Intervention to Increase Uptake of Voluntary Medical Male Circumcision in Tanzania: Spending More to Spend Less,"BACKGROUND: Although voluntary medical male circumcision (VMMC) reduces the risk of HIV acquisition, demand for services is lower among men in most at-risk age groups (ages 20-34 years). A randomized controlled trial was conducted to assess the effectiveness of locally-tailored demand creation activities (including mass media, community mobilization, and targeted service delivery) in increasing uptake of campaign-delivered VMMC among men aged 20-34 years. We conducted an economic evaluation to understand the intervention''s cost and cost-effectiveness. SETTING: Tanzania (Njombe and Tabora regions). METHODS: Cost data were collected on surgery, demand creation activities, and monitoring and supervision related to VMMC implementation across clusters in both trial arms, as well as start-up activities for the intervention arms. The Decision Makers'' Program Planning Tool was used to estimate the number of HIV infections averted and related cost savings, given the total VMMCs per cluster. Disability-adjusted life years were calculated and used to estimate incremental cost-effectiveness ratios. RESULTS: Client load was higher in the intervention arms than in the control arms: 4394 vs. 2901 in Tabora and 1797 vs. 1025 in Njombe, respectively. Despite additional costs of tailored demand creation, demand increased more than proportionally: mean costs per VMMC in the intervention arms were $62 in Tabora and $130 in Njombe, and in the control arms $70 and $191, respectively. More infections were averted in the intervention arm than in the control arm in Tabora (123 vs. 67, respectively) and in Njombe (164 vs. 102, respectively). The intervention dominated the control because it was both less costly and more effective. Cost savings were observed in both regions stemming from the antiretroviral treatment costs averted as a result of the VMMCs performed. CONCLUSIONS: Spending more to address local preferences as a way to increase uptake of VMMC can be cost-saving.",2018-01-27681,29557854,J Acquir Immune Defic Syndr,Sergio Torres-Rueda,2018,78 / 3,291-299,No,29557854,"Sergio Torres-Rueda; Mwita Wambura; Helen A Weiss; Marya Plotkin; Katharine Kripke; Joseph Chilongani; Hally Mahler; Evodius Kuringe; Maende Makokha; Augustino Hellar; Carl Schutte; Kokuhumbya J Kazaura; Daimon Simbeye; Gerry Mshana; Natasha Larke; Gissenge Lija; John Changalucha; Anna Vassall; Richard Hayes; Jonathan M Grund; Fern Terris-Prestholt; Cost and Cost-Effectiveness of a Demand Creation Intervention to Increase Uptake of Voluntary Medical Male Circumcision in Tanzania: Spending More to Spend Less, J Acquir Immune Defic Syndr, 2018 Jul 1; 78(3):1525-4135; 291-299",DALY,Tanzania,Not Stated,"Health Education or Behavior, Maternal / Neonatal / Reproductive Care, Surgical","Locally-tailored demand creation and delivery of Voluntary Medical Male Circumcision services to prevent HIV transmission vs. Standard demand creation and delivery of Voluntary Medical Male Circumcision (VMMC) services: mass media engagement, community mobilization, targeted service delivery",Njombe region,40 Years,19 Years,Male,Full,,3.00,3.00,73,United States,2015,79.71
31142,Economic Evaluation of a Pre-Hospital Protocol for Patients with Suspected Acute Stroke,"Background: In regional and rural Australia, patients experiencing ischemic stroke do not have equitable access to an intravenous recombinant tissue plasminogen activator (tPA). Although thrombolysis with tPA is a clinically proven and cost-effective treatment for eligible stroke patients, there are few economic evaluations on pre-hospital triage interventions to improve access to tPA. Aim: To describe the potential cost-effectiveness of the pre-hospital acute stroke triage (PAST) protocol implemented to provide priority transfer of appropriate patients from smaller hospitals to a primary stroke center (PSC) in regional New South Wales, Australia. Materials and methods: The PAST protocol was evaluated using a prospective and historical control design. Using aggregated administrative data, a decision analytic model was used to simulate costs and patient outcomes. During the implementation of the PAST protocol (intervention), patient data were collected prospectively at the PSC. Control patients included two groups (i) patients arriving at the PSC in the 12 months before the implementation of the PAST protocol and, (ii) patients from the geographical catchment area of the smaller regional hospitals that were previously not bypassed during the control period. Control data were collected retrospectively. The primary outcome of the economic evaluation was the additional cost per disability adjusted life years (DALYs) averted in the intervention period compared to the control period. Results: The intervention was associated with a 17 times greater odds of eligible patients receiving tPA (adjusted odds ratio, 95% CI 9.42-31.2, p < 0.05) and the majority of the associated costs were incurred during acute care and rehabilitation. Overall, the intervention was associated with an estimated net avoidance of 93.3 DALYs. The estimated average cost per DALY averted per patient in the intervention group compared to the control group was $10,921. Conclusion: Based on our simulation modeling, the pre-hospital triage intervention was a potentially cost-effective strategy for improving access to tPA therapy for patients with ischemic stroke in regional Australia.",2018-99-27694,29552550,Front Public Health,Suman Lahiry,2018,6 /,43,No,29552550,"Suman Lahiry; Christopher Levi; Joosup Kim; Dominique A Cadilhac; Andrew Searles; Economic Evaluation of a Pre-Hospital Protocol for Patients with Suspected Acute Stroke, Front Public Health, 2018; 6():2296-2565; 43",DALY,Australia,Not Stated,"Care Delivery, Diagnostic, Other",Pre-Hospital Acute Stroke triage protocol vs. Standard/Usual Care,Not Stated,Not Stated,19 Years,"Female, Male",Full,,Not Stated,Not Stated,10921,Australia,2014,10785.77
31143,The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa,"INTRODUCTION: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop multi-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these products will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex workers (FSWs). METHODS: We combined a cost model with a static model of product impact based on incidence data in South Africa to estimate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five potential rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to product use over one year. The comparator for each scenario was current levels of male condom use, while a health system perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies. We explore the additional impact of STI protection through increased uptake in a sensitivity analysis. RESULTS: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and women aged 16-24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214-$810/DALY averted among non-dominant scenarios), however, none were cost-effective among women aged 25-49 (minimum $1706/DALY averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to variation in incidence assumptions, but robust to other parameters. CONCLUSIONS: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower incidence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.",2018-99-27731,29537654,J Int AIDS Soc,Matthew Quaife,2018,21 / 3,,No,29537654,"Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman; The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa, J Int AIDS Soc, 2018 Mar; 21(3):1758-2652",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Medical Device, Pharmaceutical",Pre-exposure prophylaxis plus vaginal ring vs. Pre-exposure prophylaxis alone,Central HIV incidence,40 Years,12 Years,Female,Full,,Not Stated,Not Stated,801,United States,2016,863.76
31144,The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa,"INTRODUCTION: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop multi-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these products will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex workers (FSWs). METHODS: We combined a cost model with a static model of product impact based on incidence data in South Africa to estimate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five potential rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to product use over one year. The comparator for each scenario was current levels of male condom use, while a health system perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies. We explore the additional impact of STI protection through increased uptake in a sensitivity analysis. RESULTS: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and women aged 16-24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214-$810/DALY averted among non-dominant scenarios), however, none were cost-effective among women aged 25-49 (minimum $1706/DALY averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to variation in incidence assumptions, but robust to other parameters. CONCLUSIONS: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower incidence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.",2018-99-27731,29537654,J Int AIDS Soc,Matthew Quaife,2018,21 / 3,,No,29537654,"Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman; The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa, J Int AIDS Soc, 2018 Mar; 21(3):1758-2652",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Medical Device, Pharmaceutical",Pre-exposure prophylaxis and vaginal ring vs. Pre-exposure prophylaxis alone,Central HIV incidence,64 Years,19 Years,Female,Full,,Not Stated,Not Stated,3282,United States,2016,3539.14
31145,The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa,"INTRODUCTION: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop multi-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these products will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex workers (FSWs). METHODS: We combined a cost model with a static model of product impact based on incidence data in South Africa to estimate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five potential rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to product use over one year. The comparator for each scenario was current levels of male condom use, while a health system perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies. We explore the additional impact of STI protection through increased uptake in a sensitivity analysis. RESULTS: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and women aged 16-24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214-$810/DALY averted among non-dominant scenarios), however, none were cost-effective among women aged 25-49 (minimum $1706/DALY averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to variation in incidence assumptions, but robust to other parameters. CONCLUSIONS: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower incidence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.",2018-99-27731,29537654,J Int AIDS Soc,Matthew Quaife,2018,21 / 3,,No,29537654,"Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman; The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa, J Int AIDS Soc, 2018 Mar; 21(3):1758-2652",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Medical Device, Pharmaceutical",Pre-exposure prophylaxis plus vaginal ring vs. Pre-exposure prophylaxis alone,"Central HIV incidence, female sex workers",Not Stated,12 Years,Female,Full,,Not Stated,Not Stated,Not Stated,United States,2016,Not Stated
31146,The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa,"INTRODUCTION: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop multi-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these products will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex workers (FSWs). METHODS: We combined a cost model with a static model of product impact based on incidence data in South Africa to estimate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five potential rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to product use over one year. The comparator for each scenario was current levels of male condom use, while a health system perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies. We explore the additional impact of STI protection through increased uptake in a sensitivity analysis. RESULTS: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and women aged 16-24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214-$810/DALY averted among non-dominant scenarios), however, none were cost-effective among women aged 25-49 (minimum $1706/DALY averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to variation in incidence assumptions, but robust to other parameters. CONCLUSIONS: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower incidence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.",2018-99-27731,29537654,J Int AIDS Soc,Matthew Quaife,2018,21 / 3,,No,29537654,"Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman; The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa, J Int AIDS Soc, 2018 Mar; 21(3):1758-2652",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Medical Device, Pharmaceutical",Pre-exposure prophylaxis plus multi- purpose prevention technologies vs. Pre-exposure prophylaxis alone,Central HIV incidence,40 Years,12 Years,Female,Full,,Not Stated,Not Stated,243,United States,2016,262.04
31147,The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa,"INTRODUCTION: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop multi-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these products will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex workers (FSWs). METHODS: We combined a cost model with a static model of product impact based on incidence data in South Africa to estimate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five potential rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to product use over one year. The comparator for each scenario was current levels of male condom use, while a health system perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies. We explore the additional impact of STI protection through increased uptake in a sensitivity analysis. RESULTS: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and women aged 16-24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214-$810/DALY averted among non-dominant scenarios), however, none were cost-effective among women aged 25-49 (minimum $1706/DALY averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to variation in incidence assumptions, but robust to other parameters. CONCLUSIONS: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower incidence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.",2018-99-27731,29537654,J Int AIDS Soc,Matthew Quaife,2018,21 / 3,,No,29537654,"Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman; The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa, J Int AIDS Soc, 2018 Mar; 21(3):1758-2652",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Medical Device, Pharmaceutical",Pre-exposure prophylaxis plus multi- purpose prevention technologies vs. Pre-exposure prophylaxis alone,Central HIV incidence,64 Years,19 Years,Female,Full,,Not Stated,Not Stated,Not Stated,United States,2016,Not Stated
31148,The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa,"INTRODUCTION: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop multi-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these products will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex workers (FSWs). METHODS: We combined a cost model with a static model of product impact based on incidence data in South Africa to estimate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five potential rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to product use over one year. The comparator for each scenario was current levels of male condom use, while a health system perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies. We explore the additional impact of STI protection through increased uptake in a sensitivity analysis. RESULTS: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and women aged 16-24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214-$810/DALY averted among non-dominant scenarios), however, none were cost-effective among women aged 25-49 (minimum $1706/DALY averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to variation in incidence assumptions, but robust to other parameters. CONCLUSIONS: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower incidence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.",2018-99-27731,29537654,J Int AIDS Soc,Matthew Quaife,2018,21 / 3,,No,29537654,"Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman; The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa, J Int AIDS Soc, 2018 Mar; 21(3):1758-2652",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Medical Device, Pharmaceutical",Pre-exposure prophylaxis plus multi- purpose prevention technologies vs. Pre-exposure prophylaxis alone,"Central HIV incidence, female sex workers",64 Years,12 Years,Female,Full,,Not Stated,Not Stated,Not Stated,United States,2016,Not Stated
31149,The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa,"INTRODUCTION: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop multi-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these products will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex workers (FSWs). METHODS: We combined a cost model with a static model of product impact based on incidence data in South Africa to estimate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five potential rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to product use over one year. The comparator for each scenario was current levels of male condom use, while a health system perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies. We explore the additional impact of STI protection through increased uptake in a sensitivity analysis. RESULTS: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and women aged 16-24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214-$810/DALY averted among non-dominant scenarios), however, none were cost-effective among women aged 25-49 (minimum $1706/DALY averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to variation in incidence assumptions, but robust to other parameters. CONCLUSIONS: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower incidence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.",2018-99-27731,29537654,J Int AIDS Soc,Matthew Quaife,2018,21 / 3,,No,29537654,"Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman; The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa, J Int AIDS Soc, 2018 Mar; 21(3):1758-2652",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Medical Device, Pharmaceutical",Pre-exposure prophylaxis plus vaginal ring and multi- purpose prevention technologies vs. Pre-exposure prophylaxis plus multi- purpose prevention technologies,Central HIV incidence,40 Years,12 Years,Female,Full,,Not Stated,Not Stated,543,United States,2016,585.54
31150,The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa,"INTRODUCTION: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop multi-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these products will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex workers (FSWs). METHODS: We combined a cost model with a static model of product impact based on incidence data in South Africa to estimate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five potential rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to product use over one year. The comparator for each scenario was current levels of male condom use, while a health system perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies. We explore the additional impact of STI protection through increased uptake in a sensitivity analysis. RESULTS: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and women aged 16-24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214-$810/DALY averted among non-dominant scenarios), however, none were cost-effective among women aged 25-49 (minimum $1706/DALY averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to variation in incidence assumptions, but robust to other parameters. CONCLUSIONS: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower incidence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.",2018-99-27731,29537654,J Int AIDS Soc,Matthew Quaife,2018,21 / 3,,No,29537654,"Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman; The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa, J Int AIDS Soc, 2018 Mar; 21(3):1758-2652",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Medical Device, Pharmaceutical",Pre-exposure prophylaxis plus vaginal ring and multi- purpose prevention technologies vs. Pre-exposure prophylaxis plus multi- purpose prevention technologies,Central HIV incidence,40 Years,12 Years,Female,Full,,Not Stated,Not Stated,Not Stated,United States,2016,Not Stated
31151,The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa,"INTRODUCTION: A number of antiretroviral HIV prevention products are efficacious in preventing HIV infection. However, the sexual and reproductive health needs of many women extend beyond HIV prevention, and research is ongoing to develop multi-purpose prevention technologies (MPTs) that offer dual HIV and pregnancy protection. We do not yet know if these products will be an efficient use of constrained health resources. In this paper, we estimate the cost-effectiveness of combinations of candidate multi-purpose prevention technologies (MPTs), in South Africa among general population women and female sex workers (FSWs). METHODS: We combined a cost model with a static model of product impact based on incidence data in South Africa to estimate the cost-effectiveness of five candidate co-formulated or co-provided MPTs: oral PrEP, intravaginal ring, injectable ARV, microbicide gel and SILCS diaphragm used in concert with gel. We accounted for the preferences of end-users by predicting uptake using a discrete choice experiment (DCE). Product availability and protection were systematically varied in five potential rollout scenarios. The impact model estimated the number of infections averted through decreased incidence due to product use over one year. The comparator for each scenario was current levels of male condom use, while a health system perspective was used to estimate discounted lifetime treatment costs averted per HIV infection. Product benefit was estimated in disability-adjusted life years (DALYs) averted. Benefits from contraception were incorporated through adjusting the uptake of these products based on the DCE and through estimating the costs averted from avoiding unwanted pregnancies. We explore the additional impact of STI protection through increased uptake in a sensitivity analysis. RESULTS: At central incidence rates, all single- and multi-purpose scenarios modelled were cost-effective among FSWs and women aged 16-24, at a governmental willingness-to-pay threshold of $1175/DALY averted (range: $214-$810/DALY averted among non-dominant scenarios), however, none were cost-effective among women aged 25-49 (minimum $1706/DALY averted). The cost-effectiveness of products improved with additional protection from pregnancy. Estimates were sensitive to variation in incidence assumptions, but robust to other parameters. CONCLUSIONS: To the best of our knowledge, this is the first study to estimate the cost-effectiveness of a range of potential MPTs; suggesting that MPTs will be cost-effective among higher incidence FSWs or young women, but not among lower incidence older women. More work is needed to make attractive MPTs available to potential users who could use them effectively.",2018-99-27731,29537654,J Int AIDS Soc,Matthew Quaife,2018,21 / 3,,No,29537654,"Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman; The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa, J Int AIDS Soc, 2018 Mar; 21(3):1758-2652",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Medical Device, Pharmaceutical",Pre-exposure prophylaxis plus vaginal ring and multi- purpose prevention technologies vs. Pre-exposure prophylaxis plus multi- purpose prevention technologies,"Central HIV incidence, female sex workers",64 Years,12 Years,Female,Full,,Not Stated,Not Stated,Not Stated,United States,2016,Not Stated
31152,The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up,"Even though WHO has approved global goals for hepatitis elimination, most countries have yet to establish programs for hepatitis B and C, which account for 320 million infections and over a million deaths annually. One reason for this slow response is the paucity of robust, compelling analyses showing that national HBV/HCV programs could have a significant impact on these epidemics and save lives in a cost-effective, affordable manner. In this context, our team used an investment case approach to develop a national hepatitis action plan for South Africa, grounded in a process of intensive engagement of local stakeholders. Costs were estimated for each activity using an ingredients-based, bottom-up costing tool designed by the authors. The health impact and cost-effectiveness of the Action Plan were assessed by simulating its four priority interventions (HBV birth dose vaccination, PMTCT, HBV treatment and HCV treatment) using previously developed models calibrated to South Africa''s demographic and epidemic profile. The Action Plan is estimated to require ZAR3.8 billion (US$294 million) over 2017-2021, about 0.5% of projected government health spending. Treatment scale-up over the initial 5-year period would avert 13 000 HBV-related and 7000 HCV-related deaths. If scale up continues beyond 2021 in line with WHO goals, more than 670 000 new infections, 200 000 HBV-related deaths, and 30 000 HCV-related deaths could be averted. The incremental cost-effectiveness of the Action Plan is estimated at $3310 per DALY averted, less than the benchmark of half of per capita GDP. Our analysis suggests that the proposed scale-up can be accommodated within South Africa''s fiscal space and represents good use of scarce resources. Discussions are ongoing in South Africa on the allocation of budget to hepatitis. Our work illustrates the value and feasibility of using an investment case approach to assess the costs and relative priority of scaling up HBV/HCV services.",2018-01-04648,29529282,Prim. Health Care Res. Dev.,Robert Hecht,2018,33 / 4,528-538,No,29529282,"Robert Hecht; Emily I. McIntosh; K. Brent Smale; Lori Ann Vallis; Malin Kark; Finn Rasmussen; Sahar Ansari; Maryam Moshaverinia; Nima Roohpour; Winston W. L. Chee; Scott R. Schricker; Alireza Moshaverinia; Charu C Garg; Sarmila Mazumder; Sunita Taneja; Medha Shekhar; Sanjana Brahmawar Mohan; Anuradha Bose; Sharad D Iyengar; Rajiv Bahl; Jose Martines; Nita Bhandari; The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up, Prim. Health Care Res. Dev., 2018 May 1; 33(4):1463-4236; 528-538",DALY,South Africa,Not Stated,Immunization,Hepatitis B virus birth dose vaccination vs. Standard/Usual Care,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,Not Stated,329,United States,2016,354.78
31153,The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up,"Even though WHO has approved global goals for hepatitis elimination, most countries have yet to establish programs for hepatitis B and C, which account for 320 million infections and over a million deaths annually. One reason for this slow response is the paucity of robust, compelling analyses showing that national HBV/HCV programs could have a significant impact on these epidemics and save lives in a cost-effective, affordable manner. In this context, our team used an investment case approach to develop a national hepatitis action plan for South Africa, grounded in a process of intensive engagement of local stakeholders. Costs were estimated for each activity using an ingredients-based, bottom-up costing tool designed by the authors. The health impact and cost-effectiveness of the Action Plan were assessed by simulating its four priority interventions (HBV birth dose vaccination, PMTCT, HBV treatment and HCV treatment) using previously developed models calibrated to South Africa''s demographic and epidemic profile. The Action Plan is estimated to require ZAR3.8 billion (US$294 million) over 2017-2021, about 0.5% of projected government health spending. Treatment scale-up over the initial 5-year period would avert 13 000 HBV-related and 7000 HCV-related deaths. If scale up continues beyond 2021 in line with WHO goals, more than 670 000 new infections, 200 000 HBV-related deaths, and 30 000 HCV-related deaths could be averted. The incremental cost-effectiveness of the Action Plan is estimated at $3310 per DALY averted, less than the benchmark of half of per capita GDP. Our analysis suggests that the proposed scale-up can be accommodated within South Africa''s fiscal space and represents good use of scarce resources. Discussions are ongoing in South Africa on the allocation of budget to hepatitis. Our work illustrates the value and feasibility of using an investment case approach to assess the costs and relative priority of scaling up HBV/HCV services.",2018-01-04648,29529282,Prim. Health Care Res. Dev.,Robert Hecht,2018,33 / 4,528-538,No,29529282,"Robert Hecht; Emily I. McIntosh; K. Brent Smale; Lori Ann Vallis; Malin Kark; Finn Rasmussen; Sahar Ansari; Maryam Moshaverinia; Nima Roohpour; Winston W. L. Chee; Scott R. Schricker; Alireza Moshaverinia; Charu C Garg; Sarmila Mazumder; Sunita Taneja; Medha Shekhar; Sanjana Brahmawar Mohan; Anuradha Bose; Sharad D Iyengar; Rajiv Bahl; Jose Martines; Nita Bhandari; The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up, Prim. Health Care Res. Dev., 2018 May 1; 33(4):1463-4236; 528-538",DALY,South Africa,Not Stated,Pharmaceutical,Hepatitis C Virus treatment vs. Standard/Usual Care,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,Not Stated,2849,United States,2016,3072.21
31154,The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up,"Even though WHO has approved global goals for hepatitis elimination, most countries have yet to establish programs for hepatitis B and C, which account for 320 million infections and over a million deaths annually. One reason for this slow response is the paucity of robust, compelling analyses showing that national HBV/HCV programs could have a significant impact on these epidemics and save lives in a cost-effective, affordable manner. In this context, our team used an investment case approach to develop a national hepatitis action plan for South Africa, grounded in a process of intensive engagement of local stakeholders. Costs were estimated for each activity using an ingredients-based, bottom-up costing tool designed by the authors. The health impact and cost-effectiveness of the Action Plan were assessed by simulating its four priority interventions (HBV birth dose vaccination, PMTCT, HBV treatment and HCV treatment) using previously developed models calibrated to South Africa''s demographic and epidemic profile. The Action Plan is estimated to require ZAR3.8 billion (US$294 million) over 2017-2021, about 0.5% of projected government health spending. Treatment scale-up over the initial 5-year period would avert 13 000 HBV-related and 7000 HCV-related deaths. If scale up continues beyond 2021 in line with WHO goals, more than 670 000 new infections, 200 000 HBV-related deaths, and 30 000 HCV-related deaths could be averted. The incremental cost-effectiveness of the Action Plan is estimated at $3310 per DALY averted, less than the benchmark of half of per capita GDP. Our analysis suggests that the proposed scale-up can be accommodated within South Africa''s fiscal space and represents good use of scarce resources. Discussions are ongoing in South Africa on the allocation of budget to hepatitis. Our work illustrates the value and feasibility of using an investment case approach to assess the costs and relative priority of scaling up HBV/HCV services.",2018-01-04648,29529282,Prim. Health Care Res. Dev.,Robert Hecht,2018,33 / 4,528-538,No,29529282,"Robert Hecht; Emily I. McIntosh; K. Brent Smale; Lori Ann Vallis; Malin Kark; Finn Rasmussen; Sahar Ansari; Maryam Moshaverinia; Nima Roohpour; Winston W. L. Chee; Scott R. Schricker; Alireza Moshaverinia; Charu C Garg; Sarmila Mazumder; Sunita Taneja; Medha Shekhar; Sanjana Brahmawar Mohan; Anuradha Bose; Sharad D Iyengar; Rajiv Bahl; Jose Martines; Nita Bhandari; The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up, Prim. Health Care Res. Dev., 2018 May 1; 33(4):1463-4236; 528-538",DALY,South Africa,Not Stated,Pharmaceutical,Hepatitis B Virus treatment vs. Standard/Usual Care,Not Stated,Not Stated,19 Years,"Female, Male",Full,,3.00,Not Stated,5021,United States,2016,5414.38
31155,The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up,"Even though WHO has approved global goals for hepatitis elimination, most countries have yet to establish programs for hepatitis B and C, which account for 320 million infections and over a million deaths annually. One reason for this slow response is the paucity of robust, compelling analyses showing that national HBV/HCV programs could have a significant impact on these epidemics and save lives in a cost-effective, affordable manner. In this context, our team used an investment case approach to develop a national hepatitis action plan for South Africa, grounded in a process of intensive engagement of local stakeholders. Costs were estimated for each activity using an ingredients-based, bottom-up costing tool designed by the authors. The health impact and cost-effectiveness of the Action Plan were assessed by simulating its four priority interventions (HBV birth dose vaccination, PMTCT, HBV treatment and HCV treatment) using previously developed models calibrated to South Africa''s demographic and epidemic profile. The Action Plan is estimated to require ZAR3.8 billion (US$294 million) over 2017-2021, about 0.5% of projected government health spending. Treatment scale-up over the initial 5-year period would avert 13 000 HBV-related and 7000 HCV-related deaths. If scale up continues beyond 2021 in line with WHO goals, more than 670 000 new infections, 200 000 HBV-related deaths, and 30 000 HCV-related deaths could be averted. The incremental cost-effectiveness of the Action Plan is estimated at $3310 per DALY averted, less than the benchmark of half of per capita GDP. Our analysis suggests that the proposed scale-up can be accommodated within South Africa''s fiscal space and represents good use of scarce resources. Discussions are ongoing in South Africa on the allocation of budget to hepatitis. Our work illustrates the value and feasibility of using an investment case approach to assess the costs and relative priority of scaling up HBV/HCV services.",2018-01-04648,29529282,Prim. Health Care Res. Dev.,Robert Hecht,2018,33 / 4,528-538,No,29529282,"Robert Hecht; Emily I. McIntosh; K. Brent Smale; Lori Ann Vallis; Malin Kark; Finn Rasmussen; Sahar Ansari; Maryam Moshaverinia; Nima Roohpour; Winston W. L. Chee; Scott R. Schricker; Alireza Moshaverinia; Charu C Garg; Sarmila Mazumder; Sunita Taneja; Medha Shekhar; Sanjana Brahmawar Mohan; Anuradha Bose; Sharad D Iyengar; Rajiv Bahl; Jose Martines; Nita Bhandari; The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up, Prim. Health Care Res. Dev., 2018 May 1; 33(4):1463-4236; 528-538",DALY,South Africa,Not Stated,"Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Hepatitis B Virus prevention of mother to child transmission vs. Standard/Usual Care,Pregnant women,Not Stated,19 Years,"Female, Male",Full,,3.00,Not Stated,26241,United States,2016,28296.92
31156,The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up,"Even though WHO has approved global goals for hepatitis elimination, most countries have yet to establish programs for hepatitis B and C, which account for 320 million infections and over a million deaths annually. One reason for this slow response is the paucity of robust, compelling analyses showing that national HBV/HCV programs could have a significant impact on these epidemics and save lives in a cost-effective, affordable manner. In this context, our team used an investment case approach to develop a national hepatitis action plan for South Africa, grounded in a process of intensive engagement of local stakeholders. Costs were estimated for each activity using an ingredients-based, bottom-up costing tool designed by the authors. The health impact and cost-effectiveness of the Action Plan were assessed by simulating its four priority interventions (HBV birth dose vaccination, PMTCT, HBV treatment and HCV treatment) using previously developed models calibrated to South Africa''s demographic and epidemic profile. The Action Plan is estimated to require ZAR3.8 billion (US$294 million) over 2017-2021, about 0.5% of projected government health spending. Treatment scale-up over the initial 5-year period would avert 13 000 HBV-related and 7000 HCV-related deaths. If scale up continues beyond 2021 in line with WHO goals, more than 670 000 new infections, 200 000 HBV-related deaths, and 30 000 HCV-related deaths could be averted. The incremental cost-effectiveness of the Action Plan is estimated at $3310 per DALY averted, less than the benchmark of half of per capita GDP. Our analysis suggests that the proposed scale-up can be accommodated within South Africa''s fiscal space and represents good use of scarce resources. Discussions are ongoing in South Africa on the allocation of budget to hepatitis. Our work illustrates the value and feasibility of using an investment case approach to assess the costs and relative priority of scaling up HBV/HCV services.",2018-01-04648,29529282,Prim. Health Care Res. Dev.,Robert Hecht,2018,33 / 4,528-538,No,29529282,"Robert Hecht; Emily I. McIntosh; K. Brent Smale; Lori Ann Vallis; Malin Kark; Finn Rasmussen; Sahar Ansari; Maryam Moshaverinia; Nima Roohpour; Winston W. L. Chee; Scott R. Schricker; Alireza Moshaverinia; Charu C Garg; Sarmila Mazumder; Sunita Taneja; Medha Shekhar; Sanjana Brahmawar Mohan; Anuradha Bose; Sharad D Iyengar; Rajiv Bahl; Jose Martines; Nita Bhandari; The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up, Prim. Health Care Res. Dev., 2018 May 1; 33(4):1463-4236; 528-538",DALY,South Africa,Not Stated,"Immunization, Legislation / Regulation, Maternal / Neonatal / Reproductive Care, Pharmaceutical, Screening",Full national action plan program vs. Standard/Usual Care,Not Stated,5 Years,Not Stated,"Female, Male",Full,,3.00,Not Stated,3310,United States,2016,3569.33
31157,"Effect and cost-effectiveness of educating mothers about childhood DPT vaccination on immunisation uptake, knowledge, and perceptions in Uttar Pradesh, India: A randomised controlled trial","BACKGROUND: To assess the effect of health information on immunisation uptake in rural India, we conducted an individually randomised controlled trial of health information messages targeting the mothers of unvaccinated or incompletely vaccinated children through home visits in rural Uttar Pradesh, India. METHODS AND FINDINGS: The study tested a brief intervention that provided mothers face-to-face with information on the benefits of the tetanus vaccine. Participants were 722 mothers of children aged 0-36 months who had not received 3 doses of diphtheria-pertussis-tetanus (DPT) vaccine (DPT3). Mothers were randomly assigned in a ratio of 1:1:1 to 1 of 3 study arms: mothers in the first treatment group received information framed as a gain (e.g., the child is less likely to get tetanus and more likely to be healthy if vaccinated), mothers in the second treatment group received information framed in terms of a loss (e.g., the child is more likely to get tetanus and suffer ill health if not vaccinated), and the third arm acted as a control group, with no information given to the mother. Surveys were conducted at baseline (September 2015) and after the intervention (April 2016). The primary outcome was the proportion of children who had received DPT3 measured after 7 months of follow-up. The analysis was by intention to treat. A total of 16 (2.2%) participants were lost to follow-up. The coverage of DPT3 was 28% in the control group and 43% in the pooled information groups, giving a risk difference of 15 percentage points (95% CI: 7% to 22%, p < 0.001) and a relative risk of 1.52 (95% CI: 1.2 to 1.9, p < 0.001). The information intervention increased the rate of measles vaccination by 22 percentage points (risk difference: 22%, 95% CI: 14% to 30%, p < 0.001; relative risk: 1.53, 95% CI: 1.29 to 1.80) and the rate of full immunisation by 14 percentage points (risk difference: 14%, 95% CI: 8% to 21%, p < 0.001; relative risk: 1.72, 95% CI: 1.29 to 2.29). It had a large positive effect on knowledge of the causes, symptoms, and prevention of tetanus but no effect on perceptions of vaccine efficacy. There was no difference in the proportion of children with DPT3 between the group that received information framed as a loss and the group that received information framed as a gain (risk difference: 4%, 95% CI: -5% to 13%; p = 0.352; relative risk: 1.11, 95% CI: 0.90 to 1.36). The cost per disability-adjusted life year averted of providing information was US$186, making the intervention highly cost-effective with respect to the WHO-recommended threshold of once the gross domestic product per capita (US$793 in the case of Uttar Pradesh). Key study limitations include the modest sample size for this trial, limiting power to detect small differences in the framing of information, and the potential for contamination among households. CONCLUSIONS: Providing mothers of unvaccinated/incompletely vaccinated children with information on tetanus and the benefits of DPT vaccination substantially increased immunisation coverage and was highly cost-effective. The framing of the health information message did not appear to matter. TRIAL REGISTRATION: The trial is registered with ISRCTN, number ISRCTN84560580.",2018-99-25857,29509769,PLoS Med,Timothy Powell-Jackson,2018,15 / 3,e1002519,No,29509769,"Timothy Powell-Jackson; Camilla Fabbri; Varun Dutt; Sarah Tougher; Kultar Singh; Effect and cost-effectiveness of educating mothers about childhood DPT vaccination on immunisation uptake, knowledge, and perceptions in Uttar Pradesh, India: A randomised controlled trial, PLoS Med, 2018 Mar; 15(3):1549-1676; e1002519",DALY,India,Not Stated,Health Education or Behavior,Health education information on tetanus and the benefits of diphtheria-pertussis-tetanus vaccination vs. None,Mothers of children aged 0-36 months who had not received 3 doses of diphtheria-pertussis-tetanus (DPT) vaccine,Not Stated,19 Years,Female,Full,,Not Stated,3.00,185.57,United States,2015,202.63
31158,"Cost-effectiveness of prenatal food and micronutrient interventions on under-five mortality and stunting: Analysis of data from the MINIMat randomized trial, Bangladesh","INTRODUCTION: Nutrition interventions may have favourable as well as unfavourable effects. The Maternal and Infant Nutrition Interventions in Matlab (MINIMat), with early prenatal food and micronutrient supplementation, reduced infant mortality and were reported to be very cost-effective. However, the multiple micronutrients (MMS) supplement was associated with an increased risk of stunted growth in infancy and early childhood. This unfavourable outcome was not included in the previous cost-effectiveness analysis. The aim of this study is to evaluate whether the MINIMat interventions remain cost-effective in view of both favourable (decreased under-five-years mortality) and unfavourable (increased stunting) outcomes. METHOD: Pregnant women in rural Bangladesh, where food insecurity still is prevalent, were randomized to early (E) or usual (U) invitation to be given food supplementation and daily doses of 30 mg, or 60 mg iron with 400 mug of folic acid, or MMS with 15 micronutrients including 30 mg iron and 400 mug of folic acid. E reduced stunting at 4.5 years compared with U, MMS increased stunting at 4.5 years compared with Fe60, while the combination EMMS reduced infant mortality compared with UFe60. The outcome measure used was disability adjusted life years (DALYs), a measure of overall disease burden that combines years of life lost due to premature mortality (under five-year mortality) and years lived with disability (stunting). Incremental cost effectiveness ratios were calculated using cost data from already published studies. RESULTS: By incrementing UFe60 (standard practice) to EMMS, one DALY could be averted at a cost of US$24. CONCLUSION: When both favourable and unfavourable outcomes were included in the analysis, early prenatal food and multiple micronutrient interventions remained highly cost effective and seem to be meaningful from a public health perspective.",2018-99-25933,29447176,PLoS One,Pernilla Svefors,2018,13 / 2,e0191260,No,29447176,"Pernilla Svefors; Katarina Ekholm Selling; Rubina Shaheen; Ashraful Islam Khan; Lars-Ake Persson; Lars Lindholm; Cost-effectiveness of prenatal food and micronutrient interventions on under-five mortality and stunting: Analysis of data from the MINIMat randomized trial, Bangladesh, PLoS One , 2018; 13(2):1932-6203; e0191260",DALY,Bangladesh,Not Stated,"Maternal / Neonatal / Reproductive Care, Other",Usual timing with 60 mg iron and 400 g folic acid given from 14 weeks of gestation vs. 30 mg iron and 400 g folic acid from 14 weeks of gestation,Pregnant women,Not Stated,19 Years,Female,Full,", Lifetime",5.00,3.00,11.5,United States,2015,12.56
31159,"Cost-effectiveness of prenatal food and micronutrient interventions on under-five mortality and stunting: Analysis of data from the MINIMat randomized trial, Bangladesh","INTRODUCTION: Nutrition interventions may have favourable as well as unfavourable effects. The Maternal and Infant Nutrition Interventions in Matlab (MINIMat), with early prenatal food and micronutrient supplementation, reduced infant mortality and were reported to be very cost-effective. However, the multiple micronutrients (MMS) supplement was associated with an increased risk of stunted growth in infancy and early childhood. This unfavourable outcome was not included in the previous cost-effectiveness analysis. The aim of this study is to evaluate whether the MINIMat interventions remain cost-effective in view of both favourable (decreased under-five-years mortality) and unfavourable (increased stunting) outcomes. METHOD: Pregnant women in rural Bangladesh, where food insecurity still is prevalent, were randomized to early (E) or usual (U) invitation to be given food supplementation and daily doses of 30 mg, or 60 mg iron with 400 mug of folic acid, or MMS with 15 micronutrients including 30 mg iron and 400 mug of folic acid. E reduced stunting at 4.5 years compared with U, MMS increased stunting at 4.5 years compared with Fe60, while the combination EMMS reduced infant mortality compared with UFe60. The outcome measure used was disability adjusted life years (DALYs), a measure of overall disease burden that combines years of life lost due to premature mortality (under five-year mortality) and years lived with disability (stunting). Incremental cost effectiveness ratios were calculated using cost data from already published studies. RESULTS: By incrementing UFe60 (standard practice) to EMMS, one DALY could be averted at a cost of US$24. CONCLUSION: When both favourable and unfavourable outcomes were included in the analysis, early prenatal food and multiple micronutrient interventions remained highly cost effective and seem to be meaningful from a public health perspective.",2018-99-25933,29447176,PLoS One,Pernilla Svefors,2018,13 / 2,e0191260,No,29447176,"Pernilla Svefors; Katarina Ekholm Selling; Rubina Shaheen; Ashraful Islam Khan; Lars-Ake Persson; Lars Lindholm; Cost-effectiveness of prenatal food and micronutrient interventions on under-five mortality and stunting: Analysis of data from the MINIMat randomized trial, Bangladesh, PLoS One , 2018; 13(2):1932-6203; e0191260",DALY,Bangladesh,Not Stated,"Maternal / Neonatal / Reproductive Care, Other","Supplementation with 30 mg iron and 400 g folic acid from 14 weeks of gestation vs. Multiple micronutrients with 15 micronutrients, including 30 mg iron and 400 g folic acid from 14 weeks of gestation",Pregnant women,Not Stated,19 Years,Female,Full,", Lifetime",5.00,3.00,342.9,United States,2015,374.43
31160,"Cost-effectiveness of prenatal food and micronutrient interventions on under-five mortality and stunting: Analysis of data from the MINIMat randomized trial, Bangladesh","INTRODUCTION: Nutrition interventions may have favourable as well as unfavourable effects. The Maternal and Infant Nutrition Interventions in Matlab (MINIMat), with early prenatal food and micronutrient supplementation, reduced infant mortality and were reported to be very cost-effective. However, the multiple micronutrients (MMS) supplement was associated with an increased risk of stunted growth in infancy and early childhood. This unfavourable outcome was not included in the previous cost-effectiveness analysis. The aim of this study is to evaluate whether the MINIMat interventions remain cost-effective in view of both favourable (decreased under-five-years mortality) and unfavourable (increased stunting) outcomes. METHOD: Pregnant women in rural Bangladesh, where food insecurity still is prevalent, were randomized to early (E) or usual (U) invitation to be given food supplementation and daily doses of 30 mg, or 60 mg iron with 400 mug of folic acid, or MMS with 15 micronutrients including 30 mg iron and 400 mug of folic acid. E reduced stunting at 4.5 years compared with U, MMS increased stunting at 4.5 years compared with Fe60, while the combination EMMS reduced infant mortality compared with UFe60. The outcome measure used was disability adjusted life years (DALYs), a measure of overall disease burden that combines years of life lost due to premature mortality (under five-year mortality) and years lived with disability (stunting). Incremental cost effectiveness ratios were calculated using cost data from already published studies. RESULTS: By incrementing UFe60 (standard practice) to EMMS, one DALY could be averted at a cost of US$24. CONCLUSION: When both favourable and unfavourable outcomes were included in the analysis, early prenatal food and multiple micronutrient interventions remained highly cost effective and seem to be meaningful from a public health perspective.",2018-99-25933,29447176,PLoS One,Pernilla Svefors,2018,13 / 2,e0191260,No,29447176,"Pernilla Svefors; Katarina Ekholm Selling; Rubina Shaheen; Ashraful Islam Khan; Lars-Ake Persson; Lars Lindholm; Cost-effectiveness of prenatal food and micronutrient interventions on under-five mortality and stunting: Analysis of data from the MINIMat randomized trial, Bangladesh, PLoS One , 2018; 13(2):1932-6203; e0191260",DALY,Bangladesh,Not Stated,"Maternal / Neonatal / Reproductive Care, Other","Multiple micronutrients with 15 micronutrients, including 30 mg iron and 400 g folic acid from 14 weeks of gestation vs. Multiple micronutrients with 15 micronutrients, including 60 mg iron and 400 g folic acid from 14 weeks of gestation",Pregnant women,Not Stated,19 Years,Female,Full,", Lifetime",5.00,3.00,186.9,United States,2015,204.09
31161,Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia,"BACKGROUND: Cutaneous leishmaniasis causes a high disease burden in Colombia, and available treatments present systemic toxicity, low patient compliance, contraindications, and high costs. The purpose of this study was to estimate the cost-effectiveness of thermotherapy versus Glucantime in patients with cutaneous leishmaniasis in Colombia. METHODS: Cost-effectiveness study from an institutional perspective in 8133 incident cases. Data on therapeutic efficacy and safety were included, calculating standard costs; the outcomes were disability adjusted life years (DALYs) and the number of patients cured. The information sources were the Colombian Public Health Surveillance System, disease burden studies, and one meta-analysis of controlled clinical trials. Incremental cost-effectiveness was determined, and uncertainty was evaluated with tornado diagrams and Monte Carlo simulations. RESULTS: Thermotherapy would generate costs of US$ 501,621; the handling of adverse effects, US$ 29,224; and therapeutic failures, US$ 300,053. For Glucantime, these costs would be US$ 2,731,276, US$ 58,254, and US$ 406,298, respectively. With thermotherapy, the cost would be US$ 2062 per DALY averted and US$ 69 per patient cured; with Glucantime, the cost would be US$ 4241 per DALY averted and US$ 85 per patient cured. In Monte Carlo simulations, thermotherapy was the dominant strategy for DALYs averted in 67.9% of cases and highly cost-effective for patients cured in 72%. CONCLUSION: In Colombia, thermotherapy can be included as a cost-effective strategy for the management of cutaneous leishmaniasis. Its incorporation into clinical practice guidelines could represent savings of approximately US$ 10,488 per DALY averted and costs of US$ 116 per additional patient cured, compared to the use of Glucantime. These findings show the relevance of the incorporation of this treatment in our country and others with similar parasitological, clinical, and epidemiological patterns.",2018-01-25603,29378537,BMC Public Health,Jaiberth Antonio Cardona-Arias,2018,18 / 1,185,No,29378537,"Jaiberth Antonio Cardona-Arias; Liliana Lopez-Carvajal; Mery Patricia Tamayo-Plata; Ivan Dario Velez; Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia, BMC Public Health, 2018 Feb 5; 18(1):1471-2458; 185",DALY,Colombia,Not Stated,"Medical Device, Medical Procedure",Local heat (thermotherapy) by radiofrequency vs. Standard/Usual Care- Glucantime,Not Stated,Not Stated,Not Stated,"Female, Male",Full,,Not Stated,Not Stated,-10530.35,United States,2016,-11355.38
31162,The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study,"BACKGROUND: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt. In this context, important questions remain about the performance of different vaccine policies that target remaining serogroups. Here, we estimate the health impact and cost associated with several alternative vaccination policies in Burkina Faso. METHODS AND FINDINGS: We developed and calibrated a mathematical model of meningococcal transmission to project the disability-adjusted life years (DALYs) averted and costs associated with the current Base policy (serogroup A conjugate vaccination at 9 months, as part of the Expanded Program on Immunization [EPI], plus district-specific reactive vaccination campaigns using polyvalent meningococcal polysaccharide [PMP] vaccine in response to outbreaks) and three alternative policies: (1) Base Prime: novel polyvalent meningococcal conjugate (PMC) vaccine replaces the serogroup A conjugate in EPI and is also used in reactive campaigns; (2) Prevention 1: PMC used in EPI and in a nationwide catch-up campaign for 1-18-year-olds; and (3) Prevention 2: Prevention 1, except the nationwide campaign includes individuals up to 29 years old. Over a 30-year simulation period, Prevention 2 would avert 78% of the meningococcal cases (95% prediction interval: 63%-90%) expected under the Base policy if serogroup A is not replaced by remaining serogroups after elimination, and would avert 87% (77%-93%) of meningococcal cases if complete strain replacement occurs. Compared to the Base policy and at the PMC vaccine price of US$4 per dose, strategies that use PMC vaccine (i.e., Base Prime and Preventions 1 and 2) are expected to be cost saving if strain replacement occurs, and would cost US$51 (-US$236, US$490), US$188 (-US$97, US$626), and US$246 (-US$53, US$703) per DALY averted, respectively, if strain replacement does not occur. An important potential limitation of our study is the simplifying assumption that all circulating meningococcal serogroups can be aggregated into a single group; while this assumption is critical for model tractability, it would compromise the insights derived from our model if the effectiveness of the vaccine differs markedly between serogroups or if there are complex between-serogroup interactions that influence the frequency and magnitude of future meningitis epidemics. CONCLUSIONS: Our results suggest that a vaccination strategy that includes a catch-up nationwide immunization campaign in young adults with a PMC vaccine and the addition of this new vaccine into EPI is cost-effective and would avert a substantial portion of meningococcal cases expected under the current World Health Organization-recommended strategy of reactive vaccination. This analysis is limited to Burkina Faso and assumes that polyvalent vaccines offer equal protection against all meningococcal serogroups; further studies are needed to evaluate the robustness of this assumption and applicability for other countries in the meningitis belt.",2018-XX-25620,29364884,PLoS Med,Reza Yaesoubi,2018,15 / 1,e1002495,No,29364884,"Reza Yaesoubi; Caroline Trotter; Caroline Colijn; Maziar Yaesoubi; Anais Colombini; Stephen Resch; Paul A Kristiansen; F Marc LaForce; Ted Cohen; The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study, PLoS Med, 2018 Jan; 15(1):1549-1676; e1002495",DALY,Burkina Faso,Not Stated,"Immunization, Legislation / Regulation","Base prime: Polyvalent meningococcal conjugate vaccine at 9 mo, reactive campaign: PMC vaccine for 1 to 29 year olds vs. Base: MenAfriVac at 9 mo, reactive campaign: polyvalent meningococcal polysaccharide (PMP) vaccine for 1 to 29 year olds",Assuming strain replacement,40 Years,6 Years,"Female, Male",Full,,3.00,3.00,-193.24,United States,2016,-208.38
31163,The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study,"BACKGROUND: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt. In this context, important questions remain about the performance of different vaccine policies that target remaining serogroups. Here, we estimate the health impact and cost associated with several alternative vaccination policies in Burkina Faso. METHODS AND FINDINGS: We developed and calibrated a mathematical model of meningococcal transmission to project the disability-adjusted life years (DALYs) averted and costs associated with the current Base policy (serogroup A conjugate vaccination at 9 months, as part of the Expanded Program on Immunization [EPI], plus district-specific reactive vaccination campaigns using polyvalent meningococcal polysaccharide [PMP] vaccine in response to outbreaks) and three alternative policies: (1) Base Prime: novel polyvalent meningococcal conjugate (PMC) vaccine replaces the serogroup A conjugate in EPI and is also used in reactive campaigns; (2) Prevention 1: PMC used in EPI and in a nationwide catch-up campaign for 1-18-year-olds; and (3) Prevention 2: Prevention 1, except the nationwide campaign includes individuals up to 29 years old. Over a 30-year simulation period, Prevention 2 would avert 78% of the meningococcal cases (95% prediction interval: 63%-90%) expected under the Base policy if serogroup A is not replaced by remaining serogroups after elimination, and would avert 87% (77%-93%) of meningococcal cases if complete strain replacement occurs. Compared to the Base policy and at the PMC vaccine price of US$4 per dose, strategies that use PMC vaccine (i.e., Base Prime and Preventions 1 and 2) are expected to be cost saving if strain replacement occurs, and would cost US$51 (-US$236, US$490), US$188 (-US$97, US$626), and US$246 (-US$53, US$703) per DALY averted, respectively, if strain replacement does not occur. An important potential limitation of our study is the simplifying assumption that all circulating meningococcal serogroups can be aggregated into a single group; while this assumption is critical for model tractability, it would compromise the insights derived from our model if the effectiveness of the vaccine differs markedly between serogroups or if there are complex between-serogroup interactions that influence the frequency and magnitude of future meningitis epidemics. CONCLUSIONS: Our results suggest that a vaccination strategy that includes a catch-up nationwide immunization campaign in young adults with a PMC vaccine and the addition of this new vaccine into EPI is cost-effective and would avert a substantial portion of meningococcal cases expected under the current World Health Organization-recommended strategy of reactive vaccination. This analysis is limited to Burkina Faso and assumes that polyvalent vaccines offer equal protection against all meningococcal serogroups; further studies are needed to evaluate the robustness of this assumption and applicability for other countries in the meningitis belt.",2018-XX-25620,29364884,PLoS Med,Reza Yaesoubi,2018,15 / 1,e1002495,No,29364884,"Reza Yaesoubi; Caroline Trotter; Caroline Colijn; Maziar Yaesoubi; Anais Colombini; Stephen Resch; Paul A Kristiansen; F Marc LaForce; Ted Cohen; The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study, PLoS Med, 2018 Jan; 15(1):1549-1676; e1002495",DALY,Burkina Faso,Not Stated,"Immunization, Legislation / Regulation","Prevention 1: Polyvalent meningococcal conjugate vaccine at 9 mo, preventive campaign: PMC vaccine for 1 to 18 year olds vs. Base prime: Polyvalent meningococcal conjugate vaccine at 9 mo, reactive campaign: PMC vaccine for 1 to 29 year olds",Assuming strain replacement,18 Years,6 Years,"Female, Male",Full,,3.00,3.00,188,United States,2016,202.73
31164,The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study,"BACKGROUND: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt. In this context, important questions remain about the performance of different vaccine policies that target remaining serogroups. Here, we estimate the health impact and cost associated with several alternative vaccination policies in Burkina Faso. METHODS AND FINDINGS: We developed and calibrated a mathematical model of meningococcal transmission to project the disability-adjusted life years (DALYs) averted and costs associated with the current Base policy (serogroup A conjugate vaccination at 9 months, as part of the Expanded Program on Immunization [EPI], plus district-specific reactive vaccination campaigns using polyvalent meningococcal polysaccharide [PMP] vaccine in response to outbreaks) and three alternative policies: (1) Base Prime: novel polyvalent meningococcal conjugate (PMC) vaccine replaces the serogroup A conjugate in EPI and is also used in reactive campaigns; (2) Prevention 1: PMC used in EPI and in a nationwide catch-up campaign for 1-18-year-olds; and (3) Prevention 2: Prevention 1, except the nationwide campaign includes individuals up to 29 years old. Over a 30-year simulation period, Prevention 2 would avert 78% of the meningococcal cases (95% prediction interval: 63%-90%) expected under the Base policy if serogroup A is not replaced by remaining serogroups after elimination, and would avert 87% (77%-93%) of meningococcal cases if complete strain replacement occurs. Compared to the Base policy and at the PMC vaccine price of US$4 per dose, strategies that use PMC vaccine (i.e., Base Prime and Preventions 1 and 2) are expected to be cost saving if strain replacement occurs, and would cost US$51 (-US$236, US$490), US$188 (-US$97, US$626), and US$246 (-US$53, US$703) per DALY averted, respectively, if strain replacement does not occur. An important potential limitation of our study is the simplifying assumption that all circulating meningococcal serogroups can be aggregated into a single group; while this assumption is critical for model tractability, it would compromise the insights derived from our model if the effectiveness of the vaccine differs markedly between serogroups or if there are complex between-serogroup interactions that influence the frequency and magnitude of future meningitis epidemics. CONCLUSIONS: Our results suggest that a vaccination strategy that includes a catch-up nationwide immunization campaign in young adults with a PMC vaccine and the addition of this new vaccine into EPI is cost-effective and would avert a substantial portion of meningococcal cases expected under the current World Health Organization-recommended strategy of reactive vaccination. This analysis is limited to Burkina Faso and assumes that polyvalent vaccines offer equal protection against all meningococcal serogroups; further studies are needed to evaluate the robustness of this assumption and applicability for other countries in the meningitis belt.",2018-XX-25620,29364884,PLoS Med,Reza Yaesoubi,2018,15 / 1,e1002495,No,29364884,"Reza Yaesoubi; Caroline Trotter; Caroline Colijn; Maziar Yaesoubi; Anais Colombini; Stephen Resch; Paul A Kristiansen; F Marc LaForce; Ted Cohen; The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study, PLoS Med, 2018 Jan; 15(1):1549-1676; e1002495",DALY,Burkina Faso,Not Stated,"Immunization, Legislation / Regulation","Prevention 2: Polyvalent meningococcal conjugate vaccine at 9 mo, preventive campaign: PMC vaccine for 1 to 29 year olds vs. Prevention 1: Polyvalent meningococcal conjugate vaccine at 9 mo, preventive campaign: PMC vaccine for 1 to 18 year olds",Assuming strain replacement,40 Years,6 Years,"Female, Male",Full,,3.00,3.00,1291,United States,2016,1392.15
31165,The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study,"BACKGROUND: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt. In this context, important questions remain about the performance of different vaccine policies that target remaining serogroups. Here, we estimate the health impact and cost associated with several alternative vaccination policies in Burkina Faso. METHODS AND FINDINGS: We developed and calibrated a mathematical model of meningococcal transmission to project the disability-adjusted life years (DALYs) averted and costs associated with the current Base policy (serogroup A conjugate vaccination at 9 months, as part of the Expanded Program on Immunization [EPI], plus district-specific reactive vaccination campaigns using polyvalent meningococcal polysaccharide [PMP] vaccine in response to outbreaks) and three alternative policies: (1) Base Prime: novel polyvalent meningococcal conjugate (PMC) vaccine replaces the serogroup A conjugate in EPI and is also used in reactive campaigns; (2) Prevention 1: PMC used in EPI and in a nationwide catch-up campaign for 1-18-year-olds; and (3) Prevention 2: Prevention 1, except the nationwide campaign includes individuals up to 29 years old. Over a 30-year simulation period, Prevention 2 would avert 78% of the meningococcal cases (95% prediction interval: 63%-90%) expected under the Base policy if serogroup A is not replaced by remaining serogroups after elimination, and would avert 87% (77%-93%) of meningococcal cases if complete strain replacement occurs. Compared to the Base policy and at the PMC vaccine price of US$4 per dose, strategies that use PMC vaccine (i.e., Base Prime and Preventions 1 and 2) are expected to be cost saving if strain replacement occurs, and would cost US$51 (-US$236, US$490), US$188 (-US$97, US$626), and US$246 (-US$53, US$703) per DALY averted, respectively, if strain replacement does not occur. An important potential limitation of our study is the simplifying assumption that all circulating meningococcal serogroups can be aggregated into a single group; while this assumption is critical for model tractability, it would compromise the insights derived from our model if the effectiveness of the vaccine differs markedly between serogroups or if there are complex between-serogroup interactions that influence the frequency and magnitude of future meningitis epidemics. CONCLUSIONS: Our results suggest that a vaccination strategy that includes a catch-up nationwide immunization campaign in young adults with a PMC vaccine and the addition of this new vaccine into EPI is cost-effective and would avert a substantial portion of meningococcal cases expected under the current World Health Organization-recommended strategy of reactive vaccination. This analysis is limited to Burkina Faso and assumes that polyvalent vaccines offer equal protection against all meningococcal serogroups; further studies are needed to evaluate the robustness of this assumption and applicability for other countries in the meningitis belt.",2018-XX-25620,29364884,PLoS Med,Reza Yaesoubi,2018,15 / 1,e1002495,No,29364884,"Reza Yaesoubi; Caroline Trotter; Caroline Colijn; Maziar Yaesoubi; Anais Colombini; Stephen Resch; Paul A Kristiansen; F Marc LaForce; Ted Cohen; The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study, PLoS Med, 2018 Jan; 15(1):1549-1676; e1002495",DALY,Burkina Faso,Not Stated,"Immunization, Legislation / Regulation","Base prime: Polyvalent meningococcal conjugate vaccine at 9 mo, reactive campaign: PMC vaccine for 1 to 29 year olds vs. Base: MenAfriVac at 9 mo, reactive campaign: polyvalent meningococcal polysaccharide (PMP) vaccine for 1 to 29 year olds",Assuming no strain replacement,40 Years,6 Years,"Female, Male",Full,,3.00,3.00,51,United States,2016,55
31166,The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study,"BACKGROUND: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt. In this context, important questions remain about the performance of different vaccine policies that target remaining serogroups. Here, we estimate the health impact and cost associated with several alternative vaccination policies in Burkina Faso. METHODS AND FINDINGS: We developed and calibrated a mathematical model of meningococcal transmission to project the disability-adjusted life years (DALYs) averted and costs associated with the current Base policy (serogroup A conjugate vaccination at 9 months, as part of the Expanded Program on Immunization [EPI], plus district-specific reactive vaccination campaigns using polyvalent meningococcal polysaccharide [PMP] vaccine in response to outbreaks) and three alternative policies: (1) Base Prime: novel polyvalent meningococcal conjugate (PMC) vaccine replaces the serogroup A conjugate in EPI and is also used in reactive campaigns; (2) Prevention 1: PMC used in EPI and in a nationwide catch-up campaign for 1-18-year-olds; and (3) Prevention 2: Prevention 1, except the nationwide campaign includes individuals up to 29 years old. Over a 30-year simulation period, Prevention 2 would avert 78% of the meningococcal cases (95% prediction interval: 63%-90%) expected under the Base policy if serogroup A is not replaced by remaining serogroups after elimination, and would avert 87% (77%-93%) of meningococcal cases if complete strain replacement occurs. Compared to the Base policy and at the PMC vaccine price of US$4 per dose, strategies that use PMC vaccine (i.e., Base Prime and Preventions 1 and 2) are expected to be cost saving if strain replacement occurs, and would cost US$51 (-US$236, US$490), US$188 (-US$97, US$626), and US$246 (-US$53, US$703) per DALY averted, respectively, if strain replacement does not occur. An important potential limitation of our study is the simplifying assumption that all circulating meningococcal serogroups can be aggregated into a single group; while this assumption is critical for model tractability, it would compromise the insights derived from our model if the effectiveness of the vaccine differs markedly between serogroups or if there are complex between-serogroup interactions that influence the frequency and magnitude of future meningitis epidemics. CONCLUSIONS: Our results suggest that a vaccination strategy that includes a catch-up nationwide immunization campaign in young adults with a PMC vaccine and the addition of this new vaccine into EPI is cost-effective and would avert a substantial portion of meningococcal cases expected under the current World Health Organization-recommended strategy of reactive vaccination. This analysis is limited to Burkina Faso and assumes that polyvalent vaccines offer equal protection against all meningococcal serogroups; further studies are needed to evaluate the robustness of this assumption and applicability for other countries in the meningitis belt.",2018-XX-25620,29364884,PLoS Med,Reza Yaesoubi,2018,15 / 1,e1002495,No,29364884,"Reza Yaesoubi; Caroline Trotter; Caroline Colijn; Maziar Yaesoubi; Anais Colombini; Stephen Resch; Paul A Kristiansen; F Marc LaForce; Ted Cohen; The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study, PLoS Med, 2018 Jan; 15(1):1549-1676; e1002495",DALY,Burkina Faso,Not Stated,"Immunization, Legislation / Regulation","Prevention 1: Polyvalent meningococcal conjugate vaccine at 9 mo, preventive campaign: PMC vaccine for 1 to 18 year olds vs. Base prime: Polyvalent meningococcal conjugate vaccine at 9 mo, reactive campaign: PMC vaccine for 1 to 29 year olds",Assuming no strain replacement,40 Years,6 Years,"Female, Male",Full,,3.00,3.00,870,United States,2016,938.16
31167,The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study,"BACKGROUND: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt. In this context, important questions remain about the performance of different vaccine policies that target remaining serogroups. Here, we estimate the health impact and cost associated with several alternative vaccination policies in Burkina Faso. METHODS AND FINDINGS: We developed and calibrated a mathematical model of meningococcal transmission to project the disability-adjusted life years (DALYs) averted and costs associated with the current Base policy (serogroup A conjugate vaccination at 9 months, as part of the Expanded Program on Immunization [EPI], plus district-specific reactive vaccination campaigns using polyvalent meningococcal polysaccharide [PMP] vaccine in response to outbreaks) and three alternative policies: (1) Base Prime: novel polyvalent meningococcal conjugate (PMC) vaccine replaces the serogroup A conjugate in EPI and is also used in reactive campaigns; (2) Prevention 1: PMC used in EPI and in a nationwide catch-up campaign for 1-18-year-olds; and (3) Prevention 2: Prevention 1, except the nationwide campaign includes individuals up to 29 years old. Over a 30-year simulation period, Prevention 2 would avert 78% of the meningococcal cases (95% prediction interval: 63%-90%) expected under the Base policy if serogroup A is not replaced by remaining serogroups after elimination, and would avert 87% (77%-93%) of meningococcal cases if complete strain replacement occurs. Compared to the Base policy and at the PMC vaccine price of US$4 per dose, strategies that use PMC vaccine (i.e., Base Prime and Preventions 1 and 2) are expected to be cost saving if strain replacement occurs, and would cost US$51 (-US$236, US$490), US$188 (-US$97, US$626), and US$246 (-US$53, US$703) per DALY averted, respectively, if strain replacement does not occur. An important potential limitation of our study is the simplifying assumption that all circulating meningococcal serogroups can be aggregated into a single group; while this assumption is critical for model tractability, it would compromise the insights derived from our model if the effectiveness of the vaccine differs markedly between serogroups or if there are complex between-serogroup interactions that influence the frequency and magnitude of future meningitis epidemics. CONCLUSIONS: Our results suggest that a vaccination strategy that includes a catch-up nationwide immunization campaign in young adults with a PMC vaccine and the addition of this new vaccine into EPI is cost-effective and would avert a substantial portion of meningococcal cases expected under the current World Health Organization-recommended strategy of reactive vaccination. This analysis is limited to Burkina Faso and assumes that polyvalent vaccines offer equal protection against all meningococcal serogroups; further studies are needed to evaluate the robustness of this assumption and applicability for other countries in the meningitis belt.",2018-XX-25620,29364884,PLoS Med,Reza Yaesoubi,2018,15 / 1,e1002495,No,29364884,"Reza Yaesoubi; Caroline Trotter; Caroline Colijn; Maziar Yaesoubi; Anais Colombini; Stephen Resch; Paul A Kristiansen; F Marc LaForce; Ted Cohen; The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study, PLoS Med, 2018 Jan; 15(1):1549-1676; e1002495",DALY,Burkina Faso,Not Stated,"Immunization, Legislation / Regulation","Prevention 2: Polyvalent meningococcal conjugate vaccine at 9 mo, preventive campaign: PMC vaccine for 1 to 29 year olds vs. Prevention 1: Polyvalent meningococcal conjugate vaccine at 9 mo, preventive campaign: PMC vaccine for 1 to 18 year olds",Assuming no strain replacement,40 Years,6 Years,"Female, Male",Full,,3.00,3.00,3703.7,United States,2016,3993.88
31168,The investment case for folic acid fortification in developing countries,"There is compelling evidence that neural tube defects can be prevented through mandatory folic acid fortification. Why, then, is an investment case needed? At the core of the answer to this question is the notion that governments and individuals have limited resources for which there are many competing claims. An investment case compares the costs and benefits of folic acid fortification relative to alternative life-saving investments and informs estimates of the financing required for implementation. Our best estimate is that the cost per death averted through mandatory folic acid fortification is $957 and the cost per disability-adjusted life year is $14.90. Both compare favorably to recommended life-saving interventions, such as the rotavirus vaccine and insecticide-treated bed nets. Thus, there is a strong economic argument for mandatory folic acid fortification. Further improvements to these estimates will require better data on the costs of implementing fortification and on the costs of improving compliance where regulations are already in place.",2018-XX-25621,29363765,Ann N Y Acad Sci,John Hoddinott,2018,/,,No,29363765,"John Hoddinott; The investment case for folic acid fortification in developing countries, Ann N Y Acad Sci, 2018 Jan 24; ():0077-8923",DALY,Zambia,Not Stated,Other,Mandatory folic acid fortification vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,,Not Stated,Not Stated,14.9,United States,2017,15.73
31169,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Environmental, Pharmaceutical","No mass drug administration, Annual snail control vs. None",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,76,United States,2016,81.95
31170,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Pharmaceutical","School based treatment with mass drug administration annually, no snail control vs. No mass drug administration, Annual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,111,United States,2016,119.7
31171,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Environmental, Pharmaceutical","No mass drug administration, semiannual snail control vs. No mass drug administration, Annual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,107,United States,2016,115.38
31172,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","School based treatment with mass drug administration annually, Annual snail control vs. No mass drug administration, semiannual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,149,United States,2016,160.67
31173,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Pharmaceutical","School based treatment with mass drug administration semiannually, no snail control vs. School based treatment with mass drug administration annually, Annual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,-331.55,United States,2016,-357.52
31174,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","School based treatment with mass drug administration annually, semiannual snail control vs. School based treatment with mass drug administration annually, Annual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,232,United States,2016,250.18
31175,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","School based treatment with mass drug administration semiannually, Annual snail control vs. School based treatment with mass drug administration annually, semiannual snail control",Rural Kenyan communities: low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,-564.39,United States,2016,-608.6
31176,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","School based treatment with mass drug administration semiannually, semiannual snail control vs. School based treatment with mass drug administration annually, semiannual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,904,United States,2016,974.83
31177,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Pharmaceutical","Community-wide treatment with mass drug administration annually, No snail control vs. School based treatment with mass drug administration semiannually, semiannual snail control",Rural Kenyan communities,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,3255.71,United States,2016,3510.79
31178,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","Community-wide treatment with mass drug administration annually, Annual snail control vs. School based treatment with mass drug administration semiannually, semiannual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,1723.65,United States,2016,1858.7
31179,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","Community-wide treatment with mass drug administration annually, Semiannual snail control vs. School based treatment with mass drug administration semiannually, semiannual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,1531,United States,2016,1650.95
31180,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Pharmaceutical","Community-wide treatment with mass drug administration semiannually, No snail control vs. Community-wide treatment with mass drug administration annually, Semiannual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,10371.28,United States,2016,11183.85
31181,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","Community-wide treatment with mass drug administration semiannually, Annual snail control vs. Community-wide treatment with mass drug administration annually, Semiannual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,5472.75,United States,2016,5901.53
31182,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","Community-wide treatment with mass drug administration semiannually, Semiannual snail control vs. Community-wide treatment with mass drug administration annually, Semiannual snail control",Rural Kenyan communities: Low prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,4353,United States,2016,4694.05
31183,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Environmental, Pharmaceutical","No mass drug administration, Annual snail control vs. None",Rural Kenyan communities: high prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,29,United States,2016,31.27
31184,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Pharmaceutical","School based treatment with mass drug administration annually, no snail control vs. No mass drug administration, Annual snail control",Rural Kenyan communities: High prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,38.75,United States,2016,41.78
31185,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Environmental, Pharmaceutical","No mass drug administration, semiannual snail control vs. School based treatment with mass drug administration annually, no snail control",Rural Kenyan communities: High prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,31,United States,2016,33.43
31186,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","School based treatment with mass drug administration annually, Annual snail control vs. No mass drug administration, semiannual snail control",Rural Kenyan communities: High prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,49,United States,2016,52.84
31187,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Pharmaceutical","School based treatment with mass drug administration semiannually, no snail control vs. School based treatment with mass drug administration annually, Annual snail control",Rural Kenyan communities: high prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,-72.43,United States,2016,-78.11
31188,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","School based treatment with mass drug administration annually, semiannual snail control vs. School based treatment with mass drug administration annually, Annual snail control",Rural Kenyan communities: High prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,51,United States,2016,55
31189,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","School based treatment with mass drug administration semiannually, Annual snail control vs. School based treatment with mass drug administration annually, semiannual snail control",Rural Kenyan communities: High prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,-94.9,United States,2016,-102.33
31190,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","School based treatment with mass drug administration semiannually, semiannual snail control vs. School based treatment with mass drug administration annually, semiannual snail control",Rural Kenyan communities: High prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,238,United States,2016,256.65
31191,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Pharmaceutical","Community-wide treatment with mass drug administration annually, No snail control vs. School based treatment with mass drug administration semiannually, semiannual snail control",Rural Kenyan communities: high prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,-735.16,United States,2016,-792.76
31192,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","Community-wide treatment with mass drug administration annually, Annual snail control vs. Community-wide treatment with mass drug administration annually, No snail control",Rural Kenyan communities: high prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,1123.85,United States,2016,1211.9
31193,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","Community-wide treatment with mass drug administration annually, Semiannual snail control vs. School based treatment with mass drug administration semiannually, semiannual snail control",Rural Kenyan communities: high prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,588,United States,2016,634.07
31194,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Pharmaceutical","Community-wide treatment with mass drug administration semiannually, No snail control vs. Community-wide treatment with mass drug administration annually, Semiannual snail control",Rural Kenyan communities: high prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,-1805.71,United States,2016,-1947.19
31195,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","Community-wide treatment with mass drug administration semiannually, Annual snail control vs. Community-wide treatment with mass drug administration annually, Semiannual snail control",Rural Kenyan communities: high prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,2842.99,United States,2016,3065.73
31196,Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis,"Schistosomiasis is a parasitic disease that affects over 240 million people globally. To improve population-level disease control, there is growing interest in adding chemical-based snail control interventions to interrupt the lifecycle of Schistosoma in its snail host to reduce parasite transmission. However, this approach is not widely implemented, and given environmental concerns, the optimal conditions for when snail control is appropriate are unclear. We assessed the potential impact and cost-effectiveness of various snail control strategies. We extended previously published dynamic, age-structured transmission and cost-effectiveness models to simulate mass drug administration (MDA) and focal snail control interventions against Schistosoma haematobium across a range of low-prevalence (5-20%) and high-prevalence (25-50%) rural Kenyan communities. We simulated strategies over a 10-year period of MDA targeting school children or entire communities, snail control, and combined strategies. We measured incremental cost-effectiveness in 2016 US dollars per disability-adjusted life year and defined a strategy as optimally cost-effective when maximizing health gains (averted disability-adjusted life years) with an incremental cost-effectiveness below a Kenya-specific economic threshold. In both low- and high-prevalence settings, community-wide MDA with additional snail control reduced total disability by an additional 40% compared with school-based MDA alone. The optimally cost-effective scenario included the addition of snail control to MDA in over 95% of simulations. These results support inclusion of snail control in global guidelines and national schistosomiasis control strategies for optimal disease control, especially in settings with high prevalence, ""hot spots"" of transmission, and noncompliance to MDA.",2018-XX-25691,29301964,Proc Natl Acad Sci U S A,Nathan C Lo,2018,115 / 4,E584-E591,No,29301964,"Nathan C Lo; David Gurarie; Nara Yoon; Jean T Coulibaly; Eran Bendavid; Jason R Andrews; Charles H King; Impact and cost-effectiveness of snail control to achieve disease control targets for schistosomiasis, Proc Natl Acad Sci U S A, 2018 Jan 23; 115(4):1091-6490; E584-E591",DALY,Kenya,Not Stated,"Care Delivery, Environmental, Pharmaceutical","Community-wide treatment with mass drug administration semiannually, Semiannual snail control vs. Community-wide treatment with mass drug administration semiannually, Annual snail control",Rural Kenyan communities: High prevalence,Not Stated,19 Years,"Female, Male",Full,,3.00,3.00,141.91,United States,2016,153.03
31197,Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi,"OBJECTIVE: To investigate the economic impact of introducing targeted screening and laser photocoagulation treatment for sight-threatening diabetic retinopathy and macular edema in a setting with no previous screening or laser treatment for diabetic retinopathy in sub-Saharan Africa. MATERIALS AND METHODS: A cohort Markov model was built to compare combined targeted screening and laser treatment for patients with sight-threatening diabetic retinopathy and macular edema against no intervention. Primary outcomes were incremental cost per quality-adjusted life year (QALY) gained and per disability-adjusted life year (DALY) averted. Primary data were collected on 357 participants from the Malawi Diabetic Retinopathy Study, a prospective, observational cohort study. Multiple scenarios were explored and a probabilistic sensitivity analysis was performed. RESULTS: In the base case (age: 50 years, service utilization rate: 80%), the cost of the intervention and the years of severe visual impairment averted per patient screened were $209 and 2.2 years respectively. Applying the World Health Organization threshold of cost-effectiveness for Malawi ($679), the base case was cost-effective when QALYs were used ($400 per QALY gained) but not when DALYs were used ($766 per DALY averted). The intervention was more cost-effective when it targeted younger patients (age: 30 years) and less cost-effective when the utilization rate was lowered to 50%. CONCLUSIONS: Annual photographic screening of diabetic patients attending medical diabetes clinics in Malawi, with the provision of laser treatment for those with sight-threatening diabetic retinopathy and macular edema, appears to be cost-effective in terms of QALYs gained, in our base case scenario. Cost-effectiveness improves if services are utilized more intensively and extended to younger patients.",2018-01-25692,29300755,PLoS One,Damir Vetrini,2018,13 / 1,e0190742,No,29300755,"Damir Vetrini; Christine A Kiire; Philip I Burgess; Simon P Harding; Petros C Kayange; Khumbo Kalua; Gerald Msukwa; Nicholas A V Beare; Jason Madan; Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi, PLoS One , 2018; 13(1):1932-6203; e0190742",DALY,Malawi,Not Stated,"Medical Procedure, Screening",Targeted screening and laser photocoagulation treatment vs. None,Diabetic patients,50 Years,50 Years,"Female, Male",Full,,3.00,3.00,766,United States,2013,851.01
31198,How Could Agronomic Biofortification of Rice Be an Alternative Strategy with Higher Cost-Effectiveness for Human Iron and Zinc Deficiency in China?,"BACKGROUND: Iron and zinc deficiencies affect human health globally, especially in developing countries. Agronomic biofortification, as a strategy for alleviating these issues, has been focused on small-scale field studies, and not widely applied while lacking of cost-effectiveness analysis (CEA). OBJECTIVE: We conducted the CEA of agronomic biofortification, expressed as USD per disability-adjusted life years (DALYs) saved, to recommend a cost-effectiveness strategy that can be widely applied. METHODS: The DALYs were applied to quantify the health burden due to Fe and/or Zn deficiency and health cost of agronomic biofortification via a single, dual, or triple foliar spray of Fe, Zn, and/or pesticide in 4 (northeast, central China, southeast, and southwest) major Chinese rice-based regions. RESULTS: The current health burden by Fe or Zn malnutrition was 0.45 to 1.45 or 0.14 to 0.84 million DALYs for these 4 regions. Compared to traditional rice diets, the daily Fe and/or Zn intake from Fe and/or Zn-biofortified rice increased, and the health burden of Fe and/or Zn deficiency decreased by 28% and 48%, respectively. The cost of saving 1 DALYs ranged from US$376 to US$4989, US$194 to US$2730, and US$37.6 to US$530.1 for the single, dual, and triple foliar Fe, Zn, and/or pesticide application, respectively, due to a substantial decrease in labor costs by the latter 2 applications. CONCLUSIONS: Agronomic biofortification of rice with the triple foliar spray of Fe, Zn, and pesticide is a rapidly effective and cost-effectiveness pathway to alleviate Fe and Zn deficiency for rice-based dietary populations.",2017-XX-25999,29281918,Food Nutr Bull,Cheng-Ming Zhang,2017,/,379572117745661,No,29281918,"Cheng-Ming Zhang; Wan-Yi Zhao; A-Xiang Gao; Ting-Ting Su; Yan-Kun Wang; Yue-Qiang Zhang; Xin-Bin Zhou; Xin-Hua He; How Could Agronomic Biofortification of Rice Be an Alternative Strategy with Higher Cost-Effectiveness for Human Iron and Zinc Deficiency in China?, Food Nutr Bull, 2017 Jan 1; ():0379-5721; 379572117745661",DALY,China,Not Stated,Other,Agronomic Biofortification on Rice With Foliar Fe application alone: Optimistic scenario vs. None,Northeast rice region,Not Stated,19 Years,"Female, Male",Full,,Not Stated,Not Stated,9420.45,United States,2015,10286.67
31199,How Could Agronomic Biofortification of Rice Be an Alternative Strategy with Higher Cost-Effectiveness for Human Iron and Zinc Deficiency in China?,"BACKGROUND: Iron and zinc deficiencies affect human health globally, especially in developing countries. Agronomic biofortification, as a strategy for alleviating these issues, has been focused on small-scale field studies, and not widely applied while lacking of cost-effectiveness analysis (CEA). OBJECTIVE: We conducted the CEA of agronomic biofortification, expressed as USD per disability-adjusted life years (DALYs) saved, to recommend a cost-effectiveness strategy that can be widely applied. METHODS: The DALYs were applied to quantify the health burden due to Fe and/or Zn deficiency and health cost of agronomic biofortification via a single, dual, or triple foliar spray of Fe, Zn, and/or pesticide in 4 (northeast, central China, southeast, and southwest) major Chinese rice-based regions. RESULTS: The current health burden by Fe or Zn malnutrition was 0.45 to 1.45 or 0.14 to 0.84 million DALYs for these 4 regions. Compared to traditional rice diets, the daily Fe and/or Zn intake from Fe and/or Zn-biofortified rice increased, and the health burden of Fe and/or Zn deficiency decreased by 28% and 48%, respectively. The cost of saving 1 DALYs ranged from US$376 to US$4989, US$194 to US$2730, and US$37.6 to US$530.1 for the single, dual, and triple foliar Fe, Zn, and/or pesticide application, respectively, due to a substantial decrease in labor costs by the latter 2 applications. CONCLUSIONS: Agronomic biofortification of rice with the triple foliar spray of Fe, Zn, and pesticide is a rapidly effective and cost-effectiveness pathway to alleviate Fe and Zn deficiency for rice-based dietary populations.",2017-XX-25999,29281918,Food Nutr Bull,Cheng-Ming Zhang,2017,/,379572117745661,No,29281918,"Cheng-Ming Zhang; Wan-Yi Zhao; A-Xiang Gao; Ting-Ting Su; Yan-Kun Wang; Yue-Qiang Zhang; Xin-Bin Zhou; Xin-Hua He; How Could Agronomic Biofortification of Rice Be an Alternative Strategy with Higher Cost-Effectiveness for Human Iron and Zinc Deficiency in China?, Food Nutr Bull, 2017 Jan 1; ():0379-5721; 379572117745661",DALY,China,Not Stated,Other,Agronomic Biofortification on Rice With Foliar Fe application alone: Optimistic scenario vs. None,Central China rice region,Not Stated,19 Years,"Female, Male",Full,,Not Stated,Not Stated,5044.26,United States,2015,5508.08
31200,How Could Agronomic Biofortification of Rice Be an Alternative Strategy with Higher Cost-Effectiveness for Human Iron and Zinc Deficiency in China?,"BACKGROUND: Iron and zinc deficiencies affect human health globally, especially in developing countries. Agronomic biofortification, as a strategy for alleviating these issues, has been focused on small-scale field studies, and not widely applied while lacking of cost-effectiveness analysis (CEA). OBJECTIVE: We conducted the CEA of agronomic biofortification, expressed as USD per disability-adjusted life years (DALYs) saved, to recommend a cost-effectiveness strategy that can be widely applied. METHODS: The DALYs were applied to quantify the health burden due to Fe and/or Zn deficiency and health cost of agronomic biofortification via a single, dual, or triple foliar spray of Fe, Zn, and/or pesticide in 4 (northeast, central China, southeast, and southwest) major Chinese rice-based regions. RESULTS: The current health burden by Fe or Zn malnutrition was 0.45 to 1.45 or 0.14 to 0.84 million DALYs for these 4 regions. Compared to traditional rice diets, the daily Fe and/or Zn intake from Fe and/or Zn-biofortified rice increased, and the health burden of Fe and/or Zn deficiency decreased by 28% and 48%, respectively. The cost of saving 1 DALYs ranged from US$376 to US$4989, US$194 to US$2730, and US$37.6 to US$530.1 for the single, dual, and triple foliar Fe, Zn, and/or pesticide application, respectively, due to a substantial decrease in labor costs by the latter 2 applications. CONCLUSIONS: Agronomic biofortification of rice with the triple foliar spray of Fe, Zn, and pesticide is a rapidly effective and cost-effectiveness pathway to alleviate Fe and Zn deficiency for rice-based dietary populations.",2017-XX-25999,29281918,Food Nutr Bull,Cheng-Ming Zhang,2017,/,379572117745661,No,29281918,"Cheng-Ming Zhang; Wan-Yi Zhao; A-Xiang Gao; Ting-Ting Su; Yan-Kun Wang; Yue-Qiang Zhang; Xin-Bin Zhou; Xin-Hua He; How Could Agronomic Biofortification of Rice Be an Alternative Strategy with Higher Cost-Effectiveness for Human Iron and Zinc Deficiency in China?, Food Nutr Bull, 2017 Jan 1; ():0379-5721; 379572117745661",DALY,China,Not Stated,Other,Agronomic Biofortification on Rice With Foliar Fe application alone: Optimistic scenario vs. None,Southeast rice region,Not Stated,19 Years,"Female, Male",Full,,Not Stated,Not Stated,4054.35,United States,2015,4427.15
